US20130336933A9 - 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes - Google Patents
3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes Download PDFInfo
- Publication number
- US20130336933A9 US20130336933A9 US13/703,495 US201113703495A US2013336933A9 US 20130336933 A9 US20130336933 A9 US 20130336933A9 US 201113703495 A US201113703495 A US 201113703495A US 2013336933 A9 US2013336933 A9 US 2013336933A9
- Authority
- US
- United States
- Prior art keywords
- cells
- hepatocyte
- cell
- hps
- scaffold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003494 hepatocyte Anatomy 0.000 title claims abstract description 129
- 230000004069 differentiation Effects 0.000 title claims abstract description 40
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 247
- 238000010899 nucleation Methods 0.000 claims abstract description 32
- 238000004113 cell culture Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 49
- 230000002440 hepatic effect Effects 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 32
- 210000001900 endoderm Anatomy 0.000 claims description 23
- 239000002243 precursor Substances 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 19
- -1 poly(urethaneurea) Polymers 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 17
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 15
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 102100029819 UDP-glucuronosyltransferase 2B7 Human genes 0.000 claims description 12
- 101710200333 UDP-glucuronosyltransferase 2B7 Proteins 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims description 9
- 101000836282 Mus musculus Solute carrier organic anion transporter family member 1C1 Proteins 0.000 claims description 9
- 229940072056 alginate Drugs 0.000 claims description 9
- 229920000615 alginic acid Polymers 0.000 claims description 9
- 235000010443 alginic acid Nutrition 0.000 claims description 9
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 8
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 239000001828 Gelatine Substances 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- 230000035800 maturation Effects 0.000 claims description 8
- 229920002223 polystyrene Polymers 0.000 claims description 8
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 5
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 claims description 5
- 102100021988 Sodium/bile acid cotransporter Human genes 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 239000011435 rock Substances 0.000 claims description 5
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 claims description 4
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims description 4
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 claims description 4
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims description 4
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 claims description 4
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 claims description 4
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 claims description 4
- 101000911317 Homo sapiens Fatty acid-binding protein, liver Proteins 0.000 claims description 4
- 108091006611 SLC10A1 Proteins 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 4
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 4
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 claims description 3
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 claims description 3
- 238000012377 drug delivery Methods 0.000 claims description 3
- 238000007877 drug screening Methods 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 231100000041 toxicology testing Toxicity 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 2
- 108010085895 Laminin Proteins 0.000 claims description 2
- 102000007547 Laminin Human genes 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 2
- 229940099552 hyaluronan Drugs 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 102000001479 Member 11 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 239000011159 matrix material Substances 0.000 abstract description 16
- 239000000758 substrate Substances 0.000 abstract description 8
- 238000000576 coating method Methods 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 31
- 230000006698 induction Effects 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 239000002609 medium Substances 0.000 description 27
- 241000607479 Yersinia pestis Species 0.000 description 19
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 17
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 17
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 108010082117 matrigel Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
- 108010023082 activin A Proteins 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 102100027211 Albumin Human genes 0.000 description 8
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 8
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 8
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 8
- 229960003793 midazolam Drugs 0.000 description 8
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 101710095143 Alcohol dehydrogenase 1A Proteins 0.000 description 6
- 108091007911 GSKs Proteins 0.000 description 6
- 102000038624 GSKs Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000011339 Bile salt export pump Human genes 0.000 description 5
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 5
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 5
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 5
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- 102100037362 Fibronectin Human genes 0.000 description 4
- 108060006662 GSK3 Proteins 0.000 description 4
- 102000001267 GSK3 Human genes 0.000 description 4
- 101000836291 Homo sapiens Solute carrier organic anion transporter family member 1B1 Proteins 0.000 description 4
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 102100040198 UDP-glucuronosyltransferase 1-6 Human genes 0.000 description 4
- 101710008381 UGT1A6 Proteins 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 4
- 229960003893 phenacetin Drugs 0.000 description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 4
- 229960002695 phenobarbital Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 102100025745 Cerberus Human genes 0.000 description 3
- 241001227713 Chiron Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 101000914195 Homo sapiens Cerberus Proteins 0.000 description 3
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 3
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 3
- OUGIDAPQYNCXRA-UHFFFAOYSA-N beta-naphthoflavone Chemical compound O1C2=CC=C3C=CC=CC3=C2C(=O)C=C1C1=CC=CC=C1 OUGIDAPQYNCXRA-UHFFFAOYSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000002676 xenobiotic agent Substances 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KYVDGDMQERQKOY-UHFFFAOYSA-N 2-chloro-1-(4,5-dibromo-2-thiophenyl)ethanone Chemical compound ClCC(=O)C1=CC(Br)=C(Br)S1 KYVDGDMQERQKOY-UHFFFAOYSA-N 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 101150097704 HHEX gene Proteins 0.000 description 2
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 description 2
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 2
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 2
- 108010070507 Keratin-7 Proteins 0.000 description 2
- 108010070511 Keratin-8 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 210000004039 endoderm cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RUJZRLFQRAMGNM-UHFFFAOYSA-N 2,4-dibenzyl-3-sulfanylidene-1,2,4-thiadiazolidin-5-one Chemical compound S=C1N(CC=2C=CC=CC=2)C(=O)SN1CC1=CC=CC=C1 RUJZRLFQRAMGNM-UHFFFAOYSA-N 0.000 description 1
- ZRHRPGSSSVYBRG-UHFFFAOYSA-N 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole Chemical compound IC1=CC=CC(CSC=2OC(=NN=2)C=2C=CN=CC=2)=C1 ZRHRPGSSSVYBRG-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- 238000012605 2D cell culture Methods 0.000 description 1
- ZDEJZKULWCZIHL-UHFFFAOYSA-N 3-[1-(3-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-ylpyrrole-2,5-dione Chemical compound C12=CC=CN=C2N(CCCO)C=C1C(C(NC1=O)=O)=C1C1=CN=CC=N1 ZDEJZKULWCZIHL-UHFFFAOYSA-N 0.000 description 1
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZYISITHKPKHPKG-UHFFFAOYSA-N 4-hydroxymidazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2C(O)N=C1C1=CC=CC=C1F ZYISITHKPKHPKG-UHFFFAOYSA-N 0.000 description 1
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 102100021975 CREB-binding protein Human genes 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 1
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- JYCUVOXSZBECAY-UHFFFAOYSA-N GSK3-XIII Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C=2C=CC=CC=2)=N1 JYCUVOXSZBECAY-UHFFFAOYSA-N 0.000 description 1
- 101000650147 Gallus gallus Protein Wnt-9a Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 101150113453 Gsk3a gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 108010049606 Hepatocyte Nuclear Factors Proteins 0.000 description 1
- 102000008088 Hepatocyte Nuclear Factors Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 1
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 1
- 101100485095 Mus musculus Wnt10b gene Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108091006764 Organic cation transporters Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 101001026113 Rattus norvegicus Glutathione S-transferase alpha-1 Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108091006744 SLC22A1 Proteins 0.000 description 1
- 101710195873 Sodium/bile acid cotransporter Proteins 0.000 description 1
- 102100032416 Solute carrier family 22 member 1 Human genes 0.000 description 1
- 101001010143 Sus scrofa Glutathione S-transferase P Proteins 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 101150010310 WNT-4 gene Proteins 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 102000052548 Wnt-4 Human genes 0.000 description 1
- 108700020984 Wnt-4 Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000002236 cellular spheroid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- SAQUSDSPQYQNBG-UHFFFAOYSA-N chembl355496 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC(Br)=CC=C21 SAQUSDSPQYQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OYQYHJRSHHYEIG-UHFFFAOYSA-N ethyl carbamate;urea Chemical compound NC(N)=O.CCOC(N)=O OYQYHJRSHHYEIG-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 1
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 230000022814 xenobiotic metabolic process Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Definitions
- the present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types.
- mammalian cell culture has been refined and standardised over many years and the conditions required to permit cell growth, expansion and differentiation are well established.
- Cells can be routinely cultured on sterile plastic surfaces, such as polystyrene, often in conjunction with a matrix coating designed to more closely replicate the in vivo environment in which the cell would normally grow.
- a layer of feeder cells such as mouse embryonic fibroblasts is often required to provide a better substrate to nourish and support the proliferation of the cells.
- mammalian cells will be cultured in a supportive medium usually containing additives such as foetal calf serum, which in addition to providing various hormones and growth factors to the cells also contains a number of cellular matrix components which again helps to replicate the ideal microenvironment for cell growth.
- a supportive medium usually containing additives such as foetal calf serum, which in addition to providing various hormones and growth factors to the cells also contains a number of cellular matrix components which again helps to replicate the ideal microenvironment for cell growth.
- mammalian cell culture has a variety of downstream applications including their use in basic research, their use in drug and toxicology assays and their use in producing correctly folded recombinant mammalian proteins. More recently mammalian cell culture has been further developed to be used in the area of regenerative medicine, whereby tissue, such as skin dermal layers, is harvested and propagated for a certain time period in order to generate larger amounts of tissue for use in clinical surgery, e.g. repair of wounds after traumatic injury or repair of diseased internal organs.
- tissue such as skin dermal layers
- cells derived from primary sources are often very limited in their capacity to be further propagated and require complex formulations of growth medium and growth conditions to be successfully cultured. They also have limited use in regenerative medicine due to the problem of immune rejection.
- pluripotent stem cells can be propagated almost indefinitely, they also have the capacity to differentiate into every cell and tissue type which comprise the fully developed organism. As such, pluripotent stem cells can be an important tool in developing new drug assays and since their supply is virtually unlimited they provide a cheaper and less variable source.
- pluripotent stem cells One of the main challenges in differentiating pluripotent stem cells has been to control differentiation in such a way as to consistently produce mature, fully functional cell types rather than partly differentiated, immature precursor cells or highly heterogeneous mixtures of various cell types.
- the simplest way to differentiate pluripotent stem cells is on a 2D plastic substrate but unfortunately this often produces differentiated cells which lack the characteristic phenotype of mature cell types. This is in part due to a failure to replicate the conditions experienced by stem cells during normal embryogenesis, a process which differs from 2D culture in that it does of course take place in 3 dimensions.
- One of the ways researchers have attempted to address this has been to develop novel 3D culture systems which aim to more faithfully replicate some of the conditions experienced by cells during embryogenesis and allow them to differentiate in a more natural way. In particular, such 3D systems allow cells to interact with each other to a greater degree and allow the development of complex multicellular aggregates more akin to functioning organs than anything that can be observed using 2D cell culture.
- bioscaffolds are scalable, so that tissue growth and cell differentiation can be carried out on a larger, more economical scale. Scaffolds may be composed of a variety of materials and correct scaffold selection may be crucial in directing the growth, proliferation and differentiation of any cells which are seeded onto it.
- scaffolds are commonly composed of polymeric materials which are arranged into the form of a porous sponge.
- Bioactive agents such as extracellular matrix (ECM) components, may also be used to enhance scaffold function when deposited onto a scaffold surface, permitting greater cell adhesion.
- ECM extracellular matrix
- extracellular matrix induces cellular polarity and tissue organisation.
- a monolayer of primary hepatocytes cultured on a flat sheet of collagen is further overlaid with a second layer of collagen, a so called sandwich culture
- the cells show improved morphology and functionality compared to hepatocytes in conventional 2D cultures (Dunn, J. et al., 1991).
- the overlay causes the cells to maintain actin filaments similar to the in vivo state in contrast to the abnormal formation of stress fibres seen in the 2D control culture (Berthiaume, F. et al., 1996).
- Alginate which provides a porous non-adhesive 3D-scaffold support aggregation of hepatocytes to form strong cell-cell interaction leading to improved hepatic function (Dvir-Ginzberg, M. et al., 2003).
- the environment in the alginate matrix also supported differentiation of newborn rat hepatocytes (Dvir-Ginzberg, M. et al., 2008) and maturation of HepG2 (Elkayam, T. et al., 2006) into more mature, functional phenotypes.
- the C3A hepatic cell line showed improved drug metabolism as enzymatic activity of a number of different CYPs where increased when cultured as spheroids in alginate compared to in 2D monolayer cultures (Elkayam, T. et al., 2006).
- 3D interweaving nanofibre scaffolds which have been found to improve hepatic culture conditions (Wang, S. et al., 2008).
- porous polystyrene scaffolds provides space to enable cells to grow and differentiate and form layers that develop complex 3D cell-cell interactions (Bokhari, M.
- HepG2 respond to biochemical agents in a manner much more resembling the activity of tissues in vivo compared to cultured in 2D (Bokhari, M. et al., 2007a).
- mouse ES cells have successfully been differentiated as spheroids in perfused polyurethane foam towards hepatocytes, aiming to develop a mass differentiation culture method by combining growth factor treatment with multicellular spheroid formation (Matsumoto, K. et al., 2008).
- Liver failure and end-stage liver diseases are responsible for a huge amount of deaths around the world and is a major burden on the health care system.
- Liver transplantation remains the most successful treatment. However, the efficacy of this procedure is limited and connected to many complications such as infection or rejection. Liver transplantation also suffers from shortage of available donor organs and the treated patients will very often be referred to lifelong immunosuppression therapy. By reducing the need for organs, cell-based treatment will be of great importance to both society and to the individuals suffering from these severe diseases.
- the liver is the centre of metabolism and detoxification in the human body, and therefore huge efforts have been undertaken in order to identify a reliable source of functional cell types for in vitro testing.
- the complexity and function of the liver is not mirrored by any cell type available today.
- Methods for generation of hepatocyte-like cells from hPS cells which may be further differentiated into mature hepatocytes, often includes the formation of embryoid bodies and/or early selection based on addition of cytotoxic compounds (Rambhatla, L. et al., 2003). These selection steps, especially formation of embryoid bodies, often results in a major cell number loss and in turn low efficiency. The methods are complicated, most having very long generation times and involve several time consuming steps. Thus, there is a need for rapid and simple method for the formation of hepatocyte-like cells derived from undifferentiated hBS cells. Previous attempts to obtain hepatocyte-like cells as e.g. published in US 20030003573 results in a low yield in relation to the starting material.
- liver metabolism is very limited and the cells are also known to rapidly loose their normal phenotype and functional properties when used for in vitro applications.
- One often used alternative to primary cells are hepatic cell lines which in turn contain very low levels of (or totally lack) metabolising enzymes and have distributions of other important proteins substantially different from the native hepatocyte in vivo.
- liver metabolism is known to be species specific and thereby generating difficulties in predicting liver metabolism and toxicity in other species than the one tested.
- hPS cells may serve as an ideal renewable source of functional human hepatocytes.
- the inventor of present invention has established a number of robust protocols which allow for the seeding of either hPS cells, hepatocyte precursors or hepatocyte progenitors onto 3D bioscaffolds to reproducibly and scalably give rise to hepatocytes with a mature morphology and function.
- the invention comprises a method for improving the differentiation of human pluripotent stem cells (hPS) into hepatocyte progenitor or hepatocyte cell types, whereby the hPS cells are initially cultured on a 2-dimensional culture surface before being transferred to one of a defined set of 3D bioscaffolds for further differentiation and maturation.
- hPS cells may also initially be partially differentiated on a 2-dimensional surface into hepatocyte progenitor cell types. Subsequently, hepatocyte progenitors or hPS cells are seeded either onto a naked 3-dimensional scaffold or a scaffold which has been coated with a matrix compound and further cultured.
- the inventors have found that by initially growing and optionally initially differentiating hPS cells in a 2D environment before transferring the cells to a 3D environment significantly increases the expression of hepatocyte associated genes and the production of hepatocyte associated enzymes.
- human pluripotent stem cells refers to cells that may be derived from any source and that are capable, under appropriate conditions, of producing human progeny of different cell types that are derivatives of all of the 3 germinal layers (endoderm, mesoderm, and ectoderm). hPS cells may have the ability to form a teratoma in 8-12 week old SCID mice and/or the ability to form identifiable cells of all three germ layers in tissue culture. Included in the definition of human pluripotent stem cells are embryonic cells of various types including human embryonic stem (hES) cells, (see, e.g., Thomson, J. A. et al. (1998), Heins, N. et. al.
- hES human embryonic stem
- hPS cells suitable for use may be obtained from developing embryos.
- suitable hPS cells may be obtained from established cell lines and/or human induced pluripotent stem (hiPS) cells.
- hiPS cells refers to human induced pluripotent stem cells.
- definitive endoderm and definitive endoderm cells (DE-cells) refers to cells exhibiting such as but not limited to protein or gene expression and or/or morphology typical to cells of the definitive endoderm or a composition comprising a significant number of cells resembling the cells of the definitive endoderm.
- hepatic precursors As used herein, “hepatic precursors”, “hepatic progenitors” or “hepatic progenitor cells” refers to cells exhibiting markers such as but not limited to protein or gene expression and/or morphology typical to cells of the definitive endoderm or a composition of cell comprising a significant number of cells resembling the cells of the hepatic precursors or hepatic progenitors.
- hepatocytes or “hepatocyte-like cells (HCLC)” is intended to mean a cell type which is expressing at least some mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6.
- HCLC hepatocyte-like cells
- hESC-HEP is intended to mean a cell type derived from human embryonic stem cells which is expressing mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6.
- hiPS-HEP is intended to mean a cell type derived from induced pluripotent stem cells which is expressing mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6.
- Xeno-free refers to a cell line or cell material which has never been exposed to, directly or indirectly, material of non-human animal origin, such as cells, tissues and/or body fluids or derivatives thereof.
- Wnt-signalling refers to the pathways included in the Wnt signalling as reviewed in, e.g. Nejak-Bowen and Monga (2008).
- HDAC inhibitors refers to Histone deacetylase inhibitors.
- GSK inhibitor refers to a compound which inhibits GSK (especially GSK3, including GSK3alpha or GSK3beta).
- preferred GSK inhibitors for use in the present invention include one or more of the following: BIO (2′Z,3′E)-6-Bromoindirubin-3′-oxime (GSK3 Inhibitor IX); BIO-Acetoxime (2′Z,3′E)-6-Bromoindirubin-3′-acetoxime (GSK3 Inhibitor X); (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine (GSK3-Inhibitor XIII); Pyridocarbazole-cyclopenadienylruthenium complex (GSK3 Inhibitor XV); TDZD-8 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (GSK3beta Inhibitor I); 2-Th
- Wnt proteins function similar to GSK inhibitors and in particular, GSK inhibitors according to the present invention. They are therefore subsumed under the term GSK inhibitors.
- Exemplary Wnt proteins which may be used in the present invention include one or more of Wnt1, Wnt2, Wnt3, Wnt3a, Wnt4, Wnt10, Wnt 14, Wnt14b, Wnt15, and Wnt16, among other Wnt proteins. The use of Wnt3a is preferred.
- small molecules can be used to direct Wnt-signalling.
- GSK36 blockers or inhibitors for Wnt-signalling induction can be used for modulation of Wnt-signalling to achieve directed differentiation and maturation.
- the Wnt-signalling pathway can be induced at a later stage after initiation or before induction occurs.
- CYP is intended to mean Cytochrome P, and more specifically Cytochrome P 450, the major phase I metabolizing enzyme of the liver constituting of many different isoenzymes, such as CYP1A1, CYP1A2, CYP1B1, CYP2A6/2A7/2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7 and CYP7A1.
- GST is intended to mean glutathione transferase, and examples of subtypes thereof are GST A1-1, GST M1-1, and GST P1-1.
- UGT uridine diphosphoglucuronosyltransferase, which is a group of liver enzymes catalyzing glucuronidation activities
- Cytochrome P450 reductase also known as CPR
- CPR Cytochrome P450 reductase
- functional drug metabolising enzymes is intended to mean functional enzymes belonging to the phase I and phase II enzymes that perform chemical modifications of xenobiotics and drugs, so called drug or xenobiotic metabolism.
- the term “functional activity” means effective measurable hepatic cell function, such as a measurable transportation of drugs for drug transporters and a measurable metabolism of enzymes for the Cytochrome P450s (CYPs), commonly detected in primary human hepatocytes.
- CYPs Cytochrome P450s
- extraembryonic endoderm (E ⁇ E) is intended to mean the differentiated endodermal cells that, as to the opposite of the definitive endoderm, will constitute the compartments outside the embryo in the human development, such as the yolk sac.
- AAT is intended to mean the liver marker alpha-anti-trypsin.
- Alcohol dehydrogenase 1 is intended to mean a type of dehydrogenase enzyme that facilitates the interconversion between alcohols and aldehydes or ketones with the reduction of NAD+ to NADH. Alcohol dehydrogenase 1 serves to break down alcohols which could otherwise be toxic.
- AFP is intended to mean the liver marker alpha-fetoprotein.
- BSEP is intended to mean the bile transporter bile salt export pump.
- CK is intended to mean the liver marker cytokeratin (used interchangeably) with different subtypes such as Cytokeratin 18 (CK18/KRT18), Cytokeratin 19 (CK19/KRT19), Cytokeratin 8 (CK8) and Cytokeratin 7 (CK7).
- FGF fibroblast growth factor
- bFGF basic fibroblast growth factor
- FGF4 acidic fibroblast growth factor
- BMP Bone Morphogenic Protein, preferably of human and/or recombinant origin, and subtypes belonging thereto are e.g. BMP4 and BMP2.
- HGF Hepatocyte Growth Factor, preferably of human and/or recombinant origin.
- HNF3beta As used herein the “HNF3beta”, or “HNF3b”, used interchangeably are intended to mean hepatocyte nuclear factor 3, a transcription factor regulating gene expression in endodermal derived tissue, e.g. the liver, pancreatic islets, and adipocytes. HNF3beta may sometimes also be referred to as HNF3b or Fox2A the latter name originating from the transcription factor being a member of Forkhead box transcription factors family.
- OCT-1 is intended to mean organic cation transporter 1.
- OCT-1 is a major hepatic transporter that mediates the uptake of many organic cations from the blood into the liver where the compounds may be metabolized or secreted into the bile.
- MDR is intended to mean multi-drug resistance transporter.
- MDR 1 and 3 are members of the ATP-binding cassette (ABC) family of transporters and both are drug efflux transporters.
- ABSC ATP-binding cassette
- MDR 1 is important in regulating the traffic of drugs, peptides and xenobiotics into the body and in protecting the body against xenobiotic insults and drug toxicity, while MDR 3 is essential for phospholipid secretion into bile.
- Activin is intended to mean a TGF-beta family member that exhibits a wide range of biological activities including regulation of cellular proliferation and differentiation such as “Activin A” or “Activin B”. Activin belongs to the common TGF-beta superfamiliy of ligands.
- ROCKInhibitor is intended to mean a small molecule inhibitor of the ROCK Rho-kinase, such as Y-27632 or Fasudil.
- xeno-free is intended to mean complete circumvention of direct or in-direct exposure to non-human animal components.
- hepatocellular toxicity indicates cellular responses such as necrotic toxicity, apoptosis, mitochondrial toxicity, phospholipidosis, steatosis and bile acid transport.
- One aspect of the present invention relates to a method for differentiating human pluripotent stem cells (hPS) or hepatocyte precursor cells into mature hepatocyte or hepatocyte-like cells, the method comprising the steps:
- the cells may be seeded at a higher density on the 3D scaffolds than on the 2D cultures, such as threefold higher or fivefold higher or tenfold higher however.
- Rho kinase (rock) inhibitors may be added and/or the method can be performed under feeder-free or xeno-free conditions.
- the cells used in the methods according to present invention may be xeno-free cells, such as a xeno-free hPS cell line or cells derived from a xeno-free hPS cell line, or the cells may be human embryonic stem (hES) cells or induced pluripotent stem (iPS) cells.
- hES human embryonic stem
- iPS induced pluripotent stem
- the hepatocyte precursor cells according to present invention may be definitive endoderm (DE) cells or not and may have characteristics of fetal endoderm or hepatic endoderm.
- step ii) The transition from step i) and ii, i.e. the transfer of the cells obtained in step i) are transferred to a 3D-scaffold (step ii) may be performed after 2 to 25 days, such as 4 to 15 days.
- the 3 dimensional scaffold may be chosen from one of the following types: i) a porous alginate sponge, ii) a biodegradable poly (urethaneurea) (PUUR) polymer, iii) an emulsion-templated polystyrene, iv) a synthetic nanofibrillar composite v) a microwell device with at least one non-vertical side-wall, vi) a porous sponge fabricated from Poly (L-lactic Acid) [PLLA] or the 3 dimensional scaffold may be of another suitable type.
- the porous alginate sponge may have a pore size of 50-200 ⁇ M, whereas the pore size of the emulsion templated polystyrene scaffold is in the range of 0.1-1000 ⁇ M, such as 15-45 ⁇ M.
- present invention relates to a method as described above, wherein the 3D-scaffold is uncoated.
- the 3D-scaffold is pre-coated e.g. with one or more extracellular matrix components.
- extracellular matrix components comprise: gelatine, laminin, fibronectin, collagen, polylysine, vitronectin, hyaluronic acid, hyaluronan hydrogels, silk fibroin, chitosan or a composite of any of the forementioned.
- the 3D-scaffold of present invention may be contained within a suitable culture vessel, such as a multiwell plate including but not limited to a 6-well plate, a 12-well plate, a 24-well plate, a 48-well plate, a 96-well plate, a 384-well plate, a 1536-well plate or other suitable cell culture vessel.
- a suitable culture vessel such as a multiwell plate including but not limited to a 6-well plate, a 12-well plate, a 24-well plate, a 48-well plate, a 96-well plate, a 384-well plate, a 1536-well plate or other suitable cell culture vessel.
- the invention detailed herein comprises a process used to improve the differentiation of hPS cells towards cells having a more hepatic phenotype or cells ultimately having a partially or fully mature hepatic phenotype, this process requiring the cells to be initially cultured on a 2-dimensional culture surface before being transferred one of six possible 3-dimensional scaffolds.
- This improvement in hepatic phenotype is independent of any particular cell culture medium composition (see FIG. 9 for details of cell culture protocols employed).
- 3D scaffolds provide a better environment for the maturation and further differentiation of hPS-derived hepatocyte cells or hepatocyte progenitors compared to more traditional 2D substrates ( FIGS. 1-6 ). Further, the inventors have found a further effect when culturing the cells on a 2D surface before seeding the cells in the 3D environment.
- hepatic marker genes such as Cyp2C9, Albumin, Cyp3A4, and UGT2B7 which are all expressed more highly in cells cultured on 3D scaffolds than on 2D surfaces, regardless of cell line, matrix coating, days in culture or scaffold chosen.
- a large number of hepatic transporters (BSEP, FABP1, MRP2, NTCP, OATP2, OCT1) are expressed in much higher levels when cultured in 3D indicating more mature and functional hepatocytes.
- topographical scaffolds such as Ultraweb ( FIG. 3 ) and Aggrewell ( FIG. 5 )
- porous sponge types such as AlgiMatrix ( FIG. 2 ) and Poly-L-lysine ( FIG. 6 ) and on synthetic polymer-based scaffolds such as Artelon ( FIG. 1 ) and Alvatex ( FIG. 4 ).
- the 3D scaffold may be pre-coated with a matrix component to better resemble in vivo microenvironment normally encountered by hepatocytes.
- the matrix components gelatine and matrigel have been shown to improve the expression levels of some hepatic markers when used in conjunction with the scaffolds.
- Expression of several markers (TAT, CYP2C9, OATP2,) is higher on matrigel-coated Artelon (Artimplant) compared to uncoated ( FIG. 1 C & E; FIG. 1 A & D).
- a number of markers (TAT and UGT2B7) are significantly more highly expressed on matrigel-coated Alvatex compared to uncoated ( FIG.
- An extension of this aspect could be the addition of one or more different cell types to the hPS cells or hPS-derived hepatic progenitors which are seeded onto the 3D scaffolds, allowing co-culturing of cell lines on the 3D scaffolds.
- the cells may be seeded at different relative densities on the 3D scaffolds.
- the relative density may be a standard ⁇ 1 density (i.e. the same density as cells seeded on the 2D control surface) or a three-fold higher initial density (designated as x3) or a ten-fold higher density or any density there in between.
- FIG. 1 H & I show that expression of markers OATP2, OCT1 and TAT is higher in cells seeded at the lower x1 initial density when using uncoated Artelon (Artimplant). Expression of certain markers (e.g. CYP7A1) are also lower on cells seeded at ⁇ 3 on uncoated Alvatex compared to cells seeded at ⁇ 1, ( FIGS.
- the stage of differentiation at which the cells are seeded on the 3D scaffolds is relevant, i.e. cultured for longer being of a more mature phenotype before seeding in 3D scaffold.
- the hPS cells can be seeded in the scaffolds at several different stages of differentiation, e.g. as undifferentiated cells (day 0) or after treatment with activin A for definitive endoderm-induction (day 4-7) or as hepatic precursors (day 9, 11, 13, 14 and 15) for maturation in the 3D-scaffolds. Characterisation of such precursor cells can be carried out to determine that they are on embryonic endodermal lineage prior to seeding on scaffolds ( FIG. 11 ) or the more advanced hepatocyte precursor ( FIG.
- a related aspect concerns the differentiation regime to which the cells are subjected prior to seeding onto the scaffolds, as detailed in Example 2, in particular whether the cells are exposed to medium containing an inhibitor of the Rho-kinase ROCK, such an inhibitor being used to improve survival and re-attachment of cells after passaging and seeding both in the 2D and 3D stages.
- CYP2C9 activity was already high in cells cultured on 3D surfaces but was also observed to be elevated when cells were treated with diclophenac ( FIG. 8 ). This again shows that hepatocytes which are differentiated on 3D scaffolds have a superior metabolic hepatocytoc function when compared to 2D cultured cells.
- levels of the crucial hepatic marker CYP3A are also higher in cells cultured on matrigel-coated Alvatex (Reinnervate) and slightly higher in cells cultured on Ultraweb compared to the 2D control when cells were assayed for metabolic breakdown products of the drug Midazolam ( FIG. 8 ).
- the invention has shown several examples of improved hepatic metabolic activity in cells cultured on 3D scaffolds.
- an aspect of the present invention relates to a method wherein the hepatocyte cells or hepatocyte progenitors display elevated metabolic activity as shown by increased expression of one or more CYP markers, such as CYP2C9 or CYP3A and/or elevated levels of hepatocyte-associated genetic markers selected from the list comprising: CYP1A1, CYP1A2, CYP3A4, CYP2C9, CYP3A7, CYP7A1, MRP2, Albumin, UGT2B7, AAT, TAT.
- CYP markers such as CYP2C9 or CYP3A and/or elevated levels of hepatocyte-associated genetic markers selected from the list comprising: CYP1A1, CYP1A2, CYP3A4, CYP2C9, CYP3A7, CYP7A1, MRP2, Albumin, UGT2B7, AAT, TAT.
- an aspect of present invention relates to a method wherein the hepatocyte cells or hepatocyte progenitors display increased expression of one or more hepatic-associated transporter proteins such as BSEP, FABP1, MRP2, NTCP, OATP2, OCT1.
- hepatic-associated transporter proteins such as BSEP, FABP1, MRP2, NTCP, OATP2, OCT1.
- the present method may as discussed above, stimulate that the proportion of hepatocytes or hepatocyte progenitors compared to non-hepatocyte cells is greater than 5%, such as 10%, such as 20%, such as 30%, such as 40%, such as 50%, such as 60%, such as 70%, such as 80%, such as 90%, such as 100%.
- hepatocytes or hepatocyte progenitors are co-cultured on the 3D scaffolds with at least one other cell type chosen from, but not limited to: stellate hepatic cells, hepatic immune (Kuppfer) cells, hepatic endothelial cells, biliary epithelial cells or fibroblasts
- an aspect of the present invention relates to an hPS derived hepatocyte cell or hepatocyte progenitor cell or a composition comprising an hPS derived hepatocyte cell or hepatocyte progenitor cell obtainable by a method described herein. Further aspects of the present invention relates to the use an hPS derived hepatocyte cell or hepatocyte progenitor cell or a composition comprising an hPS derived hepatocyte cell or hepatocyte progenitor cell obtained by the methods herein in therapy, regenerative medicine, for drug screening, toxicity testing or drug delivery.
- composition may further comprise a 3D scaffold, such as but not limited to a porous alginate sponge, a biodegradable poly(urethaneurea) (PUUR) polymer, an emulsion-templated polystyrene or a synthetic nanofibrillar composite.
- a 3D scaffold such as but not limited to a porous alginate sponge, a biodegradable poly(urethaneurea) (PUUR) polymer, an emulsion-templated polystyrene or a synthetic nanofibrillar composite.
- hPS cells can be used as staring material for this invention.
- hepatocyte-like cells were derived in vitro from undifferentiated human embryonic stem cells (hESC) cultured on mEF cells (Heins, N. et al. 2004, Stem Cells).
- the cell lines used for this experiment could be, but is not limited to the hES cell line SA002, SA121, SA181, SA461 (Cellartis AB, Göteborg, Sweden, http://www.cellartis.com) and they can be propagated as described Heins, N et al. 2004.
- SA002 undifferentiated human embryonic stem cells
- SA21 SA121
- SA181, SA461 Cellartis AB, Göteborg, Sweden, http://www.cellartis.com
- These cell lines are listed in the NIH stem cell registry, the UK Stem Cell bank and the European hESC registry and are available on request.
- hPS obtained from hESC hPS obtained from hiPS (induced pluripotent stem cells) have been used for the derivation of hepatocytes for the examples of this invention.
- hiPS-HEP is intended to mean a cell type derived from induced pluripotent stem cells which is expressing mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6 (see also “Definitions”).
- xeno-free iPS cells or a xeno-free derived hES cell line such as SA611 (Cellartis AB, Goteborg, Sweden, http://www.cellartis.com) could optionally allow the entire invention to be used under xeno-free conditions to produce a xeno-free cell product.
- Hepatocytes were derived from both hES cells and human hiPS cells according to the protocols a-e, as detailed below. Before start of differentiation, the cultures were washed twice with PBS. The different media (Table 1) were prepared freshly and added from day 0 and afterwards according to the protocol overview. Medium was changed every day or every second day during the initial differentiation (ID) step, and every second or every third day afterwards. Only one cell line was used for each experiment, but optionally a second (or more) cell line could be added when the initial cell line is seeded onto the 3D scaffolds allowing co-culturing of the cells.
- Table 1 The different media (Table 1) were prepared freshly and added from day 0 and afterwards according to the protocol overview. Medium was changed every day or every second day during the initial differentiation (ID) step, and every second or every third day afterwards. Only one cell line was used for each experiment, but optionally a second (or more) cell line could be added when the initial cell line is seeded onto the 3D scaffolds allowing co-culturing of the cells.
- 2D cultures were seeded on matrigel coated culture vessels, except in experiment 114 and 116 when 2D cultures were seeded on gelatin coated culture vessels. 2D cultures were seeded in 150.000-200.000 cells/cm 2 .
- the table below shows an overview of the different experiments, which cell lines were used as starting material, the variants of differentiation protocol as outlined in FIG. 9 , time of the differentiation protocol when the cells were seeded in 3D scaffolds, time of differentiation when cells were analyzed, and whether 10 mM ROCKInhibitor was added or not to the medium at time of seeding in scaffolds (see also FIG. 9 for schematic details of protocols employed):
- Highly porous polymer matrices as a three-dimensional culture system for hepatocytes.
- the Artelon (Artimplant) and Alvatex scaffolds were soaked in 70% EtOH, the EtOH was removed and the scaffolds were washed twice with DPBS.
- Matrigel Growth factor reduced matrigel from BD, Lot no 0934 was diluted to 0.016 mg/ml in DPBS, and added to scaffolds and 2D culture dishes, incubated at RT for at least 1 h RT, then matrigel was removed immediately before use.
- Gelatine gelatin from production was added to the scaffolds and/or 2D culture dishes, incubated at RT for at least 30 min, then the gelatin was removed immediately before use.
- the cell pellet was resuspended in culture medium, cells were counted and diluted to appropriate seeding suspension. In some experiments, 10 mM Rock inhibitor was added to the culture medium at day of seeding (exp113, 114, 116, 118, 119, 120)
- hESC-HEP were derived from cell-line SA002, SA121, SA181, SA46 cultured from the DEF cultures system or SA002 cultures on mEF-layer as indicated in figure legends.
- FIGS. 1-4 Data is presented in FIGS. 1-4 and shows that hepatic genes are expressed at higher levels in hESC-HEP when cultured in 3D compared to 2D.
- the improved expression levels of the other hepatic markers in 3D cultures are supporting the finding that 3D cultures are important in hepatic differentiation of hESC.
- hESC derived hepatocyte cultures were analyzed for cytochrome P450 1A, 2C and 3A activity by incubating the substrates Phenacetin, Diclophenac and Midazolam to a final concentration of 26 ⁇ M, 9 ⁇ M and 3 ⁇ M respectively in Phenol Red-free Williams Medium E, supplemented with 0.1% Penicilline-Streptomycin 2 mM L-Glutamine and 25 mM Hepes. A volume of 100 ⁇ l diluted substrates were added per cm 2 of the well surface (e.g. 75 ul pr 48 wells). hESC derived hepatocyte cultures with substrates were incubated over night.
- LC-MS Liquid chromatography-mass spectrometry
- Cell line SA461 (Cellartis AB) was cultured and differentiated according to conditions in Examples 1 and 2, experiment 083 and then according to the scheme below:
- M5 M6 Spin down medium Seeding medium WME + SQ ⁇ WME + SQ ⁇ 50% plating media Seeding Media GA1000 GA1000 from InVitroTech 50% Plating (+0.1% PEST) (+0.1% PEST) 2 ng/ml bFGF 10 ng/ml OsM 50% WE media from (0.2 ⁇ l (1 ⁇ l InVitroTech stock/ml) stock/ml) 20 ng/ml HGF 0.1 ⁇ M DexM 50% M5 (2 ⁇ l (1.6 ⁇ l stock/ml) stock/ml) 2 ng/ml bFGF (0.2 ⁇ l stock/ml) 2 ng/ml HGF (0.2 ⁇ l stock/ml)
- Alvatex (ReInnervate) 5 times as many cells were seeded, which is a split ratio of 7.5:1. Starting out with 27 wells of 9.6 cm 2 , that is 260 cm 2 .
- Counting cells 27.9 ⁇ 10 6 cells/ml (87% viability), 3.46 ml total, 96 ⁇ 10 6 cells total.
- Well Area/ # wells Total Seeding Cells/well Total medium Scaffold type well seeded area volume/well seeded volume per well Alvatex 24 2 cm 2 14 28 cm 2 200 ⁇ l 5.6 ⁇ 10 6 0.8 (ReInnervate) 5 ⁇ 2D 24 2 cm 2 14 28 cm 2 200 ⁇ l 1.1 ⁇ 10 6 0.8
- Control medium did not contain any DMSO to be able to compare the enzyme activity with the baseline enzyme activity.
- induction or control medium was added (400 ul/well 2D cultures, 2000 ul/well in ReInnevate scaffolds) and the plate was incubated 24 h.
- Activity assay medium a protein-free medium without phenol red consisting of WE with 0.1% PEST, 2 mM L-Glutamine, 25 mm HEPES and 26 uM Phenacetin, 3 uM Midazolam and 9 uM Diclophenac.
- the protocols used for differentiation towards hepatocytes were analyzed for the formation of embryonic endoderm cells after the “endoderm induction” step, cells cultured according to protocol a) ( FIG. 11 ).
- cells were harvested for RNA and analyzed by Real-time PCR and compared to the undifferentiated cells from start of the experiment (day 0). It was shown that the differentiation protocols generated cells expressing embryonic endoderm markers (FOXA2, SOX17, HHEX, CXCR4, CER1). Furthermore, it was verified that markers (Nanog and OCT4) for undifferentiated cells was down-regulated compared to the undifferentiated starting material.
- FIG. 1 is a diagrammatic representation of FIG. 1 .
- Artelon (Artimplant) scaffold Relative expression levels of hepatic-markers on hESC-derived hepatocytes cultured either on 2D culture or 3D Artelon (Artimplant) scaffold.
- Artelon (Artimplant) is either uncoated or coated with matrix (Matrigel or gelatine) and cells seeded either at x1 density or ⁇ 3 density.
- Figure shows three independent cell lines (SA461, SA002, SA181) with cells cultured on scaffolds for either 0, 5, 11, 12, 14 or 15 days according to experiment numbers shown, protocols a) and c)
- FIG. 2 a is a diagrammatic representation of FIG. 2 a.
- FIG. 2 b
- hepatic markers on iPS-derived hepatocytes cultured either in 2D or on 3D AlgiMatrix scaffold. Cells were differentiated for 7 days prior to seeding on scaffold and analysed after 32 days culture; protocol h (Exp169a) or f (Exp169b)
- FIG. 3 is a diagrammatic representation of FIG. 3 .
- Ultraweb Relative expression of hepatic markers on hESC-derived hepatocytes cultured either on 2D or 3D Ultraweb scaffold.
- Ultraweb is either uncoated or coated with matrix (Matrigel or gelatine).
- Figures show four independent cell lines (SA002, SA461, SAl21 and SA181) with cells cultured on scaffolds for either 4, 5, 7 or 14 days, protocols a), b), c), d)
- FIG. 4 a
- Alvatex is either uncoated or coated with matrix (Matrigel or gelatine) and cells seeded either at ⁇ 1 density or ⁇ 3 density.
- Figure shows four independent cell lines (SA461, SA002, SA181 and SA121) with cells cultured on scaffolds for either 0, 4, 9, 11, 13 or 14 days according to experiment numbers shown, protocols a), c), d)
- FIG. 4 b
- Alvatex is either uncoated or coated with matrix (Matrigel or Fibronectin) and cells seeded after 7 days 2D culture at x6 density that of 2D cultures from which cells were harvested.
- Figure shows one independent iPS line (IMR90) with cells cultured on scaffolds for up to 29 days before analysis; culture protocol f.
- hepatic-markers on hESC-derived hepatocytes cultured either on 2D culture or 3D Aggrewell scaffold.
- Aggrewell is coated with matrix (Fibronectin) prior to seeding with cells cultured in 2D for 11 days; culturing according to protocol f) and cells seeded at either 100 or 200 aggregates per well.
- Figure shows one independent hESC line (SA181) with cells cultured on scaffolds for up to 25 days before analysis.
- HAC Poly-l-lysine 3D scaffold
- FIG. 7 is a diagrammatic representation of FIG. 7 .
- Figure shows relative CYP activity of hESC-derived hepatocytes cultured either on Alvatex, Ultraweb or 2D control, with cells treated with either APAP, Midazolam or Diclofenac to induce CYP response and mimic hepatic metabolic activity.
- FIG. 8 is a diagrammatic representation of FIG. 8 .
- Figures show CYP response in hESC-derived hepatocytes cultured either on Alvatex (Reinnervate) or 2D control, cells induced with Diclofenac to mimic hepatic liver activity. Activity assay performed at day 23 and day 29 as indicated.
- FIG. 9 is a diagrammatic representation of FIG. 9 .
- Protocol a (exp 113, 114, 118, 119, 120).
- Protocol f (exp169b, 172, 175SA181)
- Protocol g (exp139, 140, 148, 175SA121, 177SA121, CYP3A induction)
- Protocol h (exp169a, 177SA181, CYP3A induction)
- ITS (1x, 10 ⁇ l/ml) 3 ng/ml glucagon M5 M6 WME + SQ WME + SQ ( ⁇ GA1000) ( ⁇ GA1000) (+1% Glutamax + (+1% Glutamax + 0.1% PEST) 0.1% PEST) 2 ng/ml bFGF 2 ng/ml bFGF 20 ng/ml HGF 20 ng/ml HGF 10 ng/ml OsM 0.1 ⁇ M DexM
- FIG. 10 is a diagrammatic representation of FIG. 10 .
- FIG. 11 a is a diagrammatic representation of FIG. 11 .
- FIG. 11 b is a diagrammatic representation of FIG. 11 .
- FIG. 12 is a diagrammatic representation of FIG. 12 .
- hepatic progenitor markers AFP, EpCAM, FOXA2, HNF4-a, KRT19, KRT8
- hESC cells cultured in 2D format for 11 days prior to seeding on 3D scaffolds; cell lines SA121 and SA181, cultured according to protocol g).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types.
- Mammalian Cell Culture
- The process of mammalian cell culture has been refined and standardised over many years and the conditions required to permit cell growth, expansion and differentiation are well established. Cells can be routinely cultured on sterile plastic surfaces, such as polystyrene, often in conjunction with a matrix coating designed to more closely replicate the in vivo environment in which the cell would normally grow. In the case of embryonic stem cells, a layer of feeder cells such as mouse embryonic fibroblasts is often required to provide a better substrate to nourish and support the proliferation of the cells. Typically, mammalian cells will be cultured in a supportive medium usually containing additives such as foetal calf serum, which in addition to providing various hormones and growth factors to the cells also contains a number of cellular matrix components which again helps to replicate the ideal microenvironment for cell growth.
- Currently, mammalian cell culture has a variety of downstream applications including their use in basic research, their use in drug and toxicology assays and their use in producing correctly folded recombinant mammalian proteins. More recently mammalian cell culture has been further developed to be used in the area of regenerative medicine, whereby tissue, such as skin dermal layers, is harvested and propagated for a certain time period in order to generate larger amounts of tissue for use in clinical surgery, e.g. repair of wounds after traumatic injury or repair of diseased internal organs. However, cells derived from primary sources are often very limited in their capacity to be further propagated and require complex formulations of growth medium and growth conditions to be successfully cultured. They also have limited use in regenerative medicine due to the problem of immune rejection.
- Recently, there have been a number of developments in the field of embryonic stem cell research which aim to traverse these barriers. Not only can such pluripotent stem cells be propagated almost indefinitely, they also have the capacity to differentiate into every cell and tissue type which comprise the fully developed organism. As such, pluripotent stem cells can be an important tool in developing new drug assays and since their supply is virtually unlimited they provide a cheaper and less variable source.
- 3D Bioscaffolds
- One of the main challenges in differentiating pluripotent stem cells has been to control differentiation in such a way as to consistently produce mature, fully functional cell types rather than partly differentiated, immature precursor cells or highly heterogeneous mixtures of various cell types. The simplest way to differentiate pluripotent stem cells is on a 2D plastic substrate but unfortunately this often produces differentiated cells which lack the characteristic phenotype of mature cell types. This is in part due to a failure to replicate the conditions experienced by stem cells during normal embryogenesis, a process which differs from 2D culture in that it does of course take place in 3 dimensions. One of the ways researchers have attempted to address this has been to develop novel 3D culture systems which aim to more faithfully replicate some of the conditions experienced by cells during embryogenesis and allow them to differentiate in a more natural way. In particular, such 3D systems allow cells to interact with each other to a greater degree and allow the development of complex multicellular aggregates more akin to functioning organs than anything that can be observed using 2D cell culture.
- 3D systems rely on the presence of a bioactive scaffold onto which the cells can be seeded and to which they can adhere. Such a scaffold must help to direct the growth and proliferation of cells in a desired 3D configuration and may also be required to provide certain molecular signals which help the cells to form the desired structures. Another important requirement of bioscaffolds is that they are scalable, so that tissue growth and cell differentiation can be carried out on a larger, more economical scale. Scaffolds may be composed of a variety of materials and correct scaffold selection may be crucial in directing the growth, proliferation and differentiation of any cells which are seeded onto it. For example, scaffolds are commonly composed of polymeric materials which are arranged into the form of a porous sponge. Cells seeded into this scaffold can then attach and grow inside the pore structure of the scaffold through the network of interconnecting tunnels and channels inside the scaffold, with pore size being an important consideration when selecting an appropriate scaffold. Bioactive agents, such as extracellular matrix (ECM) components, may also be used to enhance scaffold function when deposited onto a scaffold surface, permitting greater cell adhesion. The end result is to provide cells with an in vitro environment in which they can interact more realistically and in a manner which more closely resembles their normal in vivo home.
- In several culture systems, the addition of extracellular matrix induces cellular polarity and tissue organisation. For example, when a monolayer of primary hepatocytes cultured on a flat sheet of collagen is further overlaid with a second layer of collagen, a so called sandwich culture, the cells show improved morphology and functionality compared to hepatocytes in conventional 2D cultures (Dunn, J. et al., 1991). The overlay causes the cells to maintain actin filaments similar to the in vivo state in contrast to the abnormal formation of stress fibres seen in the 2D control culture (Berthiaume, F. et al., 1996). The more physiological relevant cytoskeletal organisation and the following cell polarity and shape might be responsible for the improved hepatic functionality, although it was later argued that the beneficial effects of the sandwich culture primarily arise from the improved cell-cell contact rather than the cell contact to the extracellular matrix (Hamilton, G. et al., 2001). Collagen scaffolds has also been employed in the differentiation of embryonic stem cells into hepatocytes. Baharvand and co-workers found that differentiation of hepatocyte-like cells inside collagen scaffolds improved morphological features, gene expression pattern and metabolic activity compared to cells differentiated in traditional 2D (Baharvand, H. et al., 2006).
- Alginate, which provides a porous non-adhesive 3D-scaffold support aggregation of hepatocytes to form strong cell-cell interaction leading to improved hepatic function (Dvir-Ginzberg, M. et al., 2003). The environment in the alginate matrix also supported differentiation of newborn rat hepatocytes (Dvir-Ginzberg, M. et al., 2008) and maturation of HepG2 (Elkayam, T. et al., 2006) into more mature, functional phenotypes. Additionally, the C3A hepatic cell line showed improved drug metabolism as enzymatic activity of a number of different CYPs where increased when cultured as spheroids in alginate compared to in 2D monolayer cultures (Elkayam, T. et al., 2006). Recently several new products for providing 3D scaffolds to support cell culture have been launched on the market, including 3D interweaving nanofibre scaffolds which have been found to improve hepatic culture conditions (Wang, S. et al., 2008). Alternatively, porous polystyrene scaffolds provides space to enable cells to grow and differentiate and form layers that develop complex 3D cell-cell interactions (Bokhari, M. et al., 2007a; Bokhari, M et al., 2007b). In these scaffolds, HepG2 respond to biochemical agents in a manner much more resembling the activity of tissues in vivo compared to cultured in 2D (Bokhari, M. et al., 2007a). Additionally, mouse ES cells have successfully been differentiated as spheroids in perfused polyurethane foam towards hepatocytes, aiming to develop a mass differentiation culture method by combining growth factor treatment with multicellular spheroid formation (Matsumoto, K. et al., 2008).
- Hepatocyte Cell Culture
- Liver failure and end-stage liver diseases are responsible for a huge amount of deaths around the world and is a major burden on the health care system. Liver transplantation remains the most successful treatment. However, the efficacy of this procedure is limited and connected to many complications such as infection or rejection. Liver transplantation also suffers from shortage of available donor organs and the treated patients will very often be referred to lifelong immunosuppression therapy. By reducing the need for organs, cell-based treatment will be of great importance to both society and to the individuals suffering from these severe diseases.
- Furthermore, the liver is the centre of metabolism and detoxification in the human body, and therefore huge efforts have been undertaken in order to identify a reliable source of functional cell types for in vitro testing. Unfortunately, the complexity and function of the liver is not mirrored by any cell type available today.
- Methods for generation of hepatocyte-like cells from hPS cells, which may be further differentiated into mature hepatocytes, often includes the formation of embryoid bodies and/or early selection based on addition of cytotoxic compounds (Rambhatla, L. et al., 2003). These selection steps, especially formation of embryoid bodies, often results in a major cell number loss and in turn low efficiency. The methods are complicated, most having very long generation times and involve several time consuming steps. Thus, there is a need for rapid and simple method for the formation of hepatocyte-like cells derived from undifferentiated hBS cells. Previous attempts to obtain hepatocyte-like cells as e.g. published in US 20030003573 results in a low yield in relation to the starting material. Furthermore, the availability of primary human liver cells is very limited and the cells are also known to rapidly loose their normal phenotype and functional properties when used for in vitro applications. One often used alternative to primary cells are hepatic cell lines which in turn contain very low levels of (or totally lack) metabolising enzymes and have distributions of other important proteins substantially different from the native hepatocyte in vivo. Thus, many tests are still performed using animal material, even though liver metabolism is known to be species specific and thereby generating difficulties in predicting liver metabolism and toxicity in other species than the one tested.
- In pharmaceutical development, adverse liver reactions remain the most prominent side effect. Therefore early prediction of human liver toxicity liabilities is of paramount importance when selecting compounds to enter clinical trials. Efforts to improve capabilities in this area must address both the availability question and development of models, which provide greater coverage for the complex biological processes which coincide to induce adverse liver injury in humans.
- Accordingly there is an urgent need for a model system that mimics human liver cells and that is able to predict effects of candidate molecules in the development of new drugs or chemicals. Regarding both availability and physiological relevance, hPS cells may serve as an ideal renewable source of functional human hepatocytes.
- The inventor of present invention has established a number of robust protocols which allow for the seeding of either hPS cells, hepatocyte precursors or hepatocyte progenitors onto 3D bioscaffolds to reproducibly and scalably give rise to hepatocytes with a mature morphology and function.
- The invention comprises a method for improving the differentiation of human pluripotent stem cells (hPS) into hepatocyte progenitor or hepatocyte cell types, whereby the hPS cells are initially cultured on a 2-dimensional culture surface before being transferred to one of a defined set of 3D bioscaffolds for further differentiation and maturation. hPS cells may also initially be partially differentiated on a 2-dimensional surface into hepatocyte progenitor cell types. Subsequently, hepatocyte progenitors or hPS cells are seeded either onto a naked 3-dimensional scaffold or a scaffold which has been coated with a matrix compound and further cultured.
- As an important aspect of the invention, the inventors have found that by initially growing and optionally initially differentiating hPS cells in a 2D environment before transferring the cells to a 3D environment significantly increases the expression of hepatocyte associated genes and the production of hepatocyte associated enzymes.
- As used herein, “human pluripotent stem cells” (hPS) refers to cells that may be derived from any source and that are capable, under appropriate conditions, of producing human progeny of different cell types that are derivatives of all of the 3 germinal layers (endoderm, mesoderm, and ectoderm). hPS cells may have the ability to form a teratoma in 8-12 week old SCID mice and/or the ability to form identifiable cells of all three germ layers in tissue culture. Included in the definition of human pluripotent stem cells are embryonic cells of various types including human embryonic stem (hES) cells, (see, e.g., Thomson, J. A. et al. (1998), Heins, N. et. al. (2004), as well as induced pluripotent stem cells [see, e.g. Yu, J. et al., (2007); Takahashi, K. et al. (2007)]. The various methods and other embodiments described herein may require or utilise hPS cells from a variety of sources. For example, hPS cells suitable for use may be obtained from developing embryos. Additionally or alternatively, suitable hPS cells may be obtained from established cell lines and/or human induced pluripotent stem (hiPS) cells.
- As used herein “hiPS cells” (also “iPS”) refers to human induced pluripotent stem cells.
- As used herein “definitive endoderm (DE)” and definitive endoderm cells (DE-cells) refers to cells exhibiting such as but not limited to protein or gene expression and or/or morphology typical to cells of the definitive endoderm or a composition comprising a significant number of cells resembling the cells of the definitive endoderm.
- As used herein, “hepatic precursors”, “hepatic progenitors” or “hepatic progenitor cells” refers to cells exhibiting markers such as but not limited to protein or gene expression and/or morphology typical to cells of the definitive endoderm or a composition of cell comprising a significant number of cells resembling the cells of the hepatic precursors or hepatic progenitors.
- As used herein, “hepatocytes” or “hepatocyte-like cells (HCLC)” is intended to mean a cell type which is expressing at least some mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6.
- As used herein, “hESC-HEP” is intended to mean a cell type derived from human embryonic stem cells which is expressing mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6.
- As used herein, “hiPS-HEP” is intended to mean a cell type derived from induced pluripotent stem cells which is expressing mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6.
- As used herein, “Xeno-free” refers to a cell line or cell material which has never been exposed to, directly or indirectly, material of non-human animal origin, such as cells, tissues and/or body fluids or derivatives thereof.
- As used herein, “Wnt-signalling” refers to the pathways included in the Wnt signalling as reviewed in, e.g. Nejak-Bowen and Monga (2008).
- As used herein HDAC inhibitors refers to Histone deacetylase inhibitors.
- As used herein, “GSK inhibitor” refers to a compound which inhibits GSK (especially GSK3, including GSK3alpha or GSK3beta). Examples of preferred GSK inhibitors for use in the present invention include one or more of the following: BIO (2′Z,3′E)-6-Bromoindirubin-3′-oxime (GSK3 Inhibitor IX); BIO-Acetoxime (2′Z,3′E)-6-Bromoindirubin-3′-acetoxime (GSK3 Inhibitor X); (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine (GSK3-Inhibitor XIII); Pyridocarbazole-cyclopenadienylruthenium complex (GSK3 Inhibitor XV); TDZD-8 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (GSK3beta Inhibitor I); 2-Thio(3-iodobenzyl)-5-(l-pyridyl)[l,3,4]-oxadiazole (GSK3beta Inhibitor II); OTDZT 2,4-Dibenzyl-5-oxothiadiazolidine-3-thione (GSK3beta Inhibitor III); alpha-4-Dibromoacetophenone (GSK3beta Inhibitor VII); AR-AO 14418 N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea (GSK-3beta Inhibitor VIII); 3-(l-(3-Hydroxypropyl)-lH-pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-yl-pyrrole-2,5-dione (GSK-3beta Inhibitor XI); TWSI 19 pyrrolopyrimidine compound (GSK3beta Inhibitor XII); L803 H-KEAPPAPPQSpP-NH2 or its Myristoylated form (GSK3beta Inhibitor XIII); and 2-Chloro-l-(4,5-dibromo-thiophen-2-yl)ethanone (GSK3beta Inhibitor VI); and Aminopyrimidine CHIR99021. In addition, numerous wingless proteins or Wnt proteins function similar to GSK inhibitors and in particular, GSK inhibitors according to the present invention. They are therefore subsumed under the term GSK inhibitors. Exemplary Wnt proteins which may be used in the present invention include one or more of Wnt1, Wnt2, Wnt3, Wnt3a, Wnt4, Wnt10,
Wnt 14, Wnt14b, Wnt15, and Wnt16, among other Wnt proteins. The use of Wnt3a is preferred. - Furthermore small molecules can be used to direct Wnt-signalling. As well GSK36 blockers or inhibitors for Wnt-signalling induction can be used for modulation of Wnt-signalling to achieve directed differentiation and maturation. The Wnt-signalling pathway can be induced at a later stage after initiation or before induction occurs.
- As used herein “CYP” is intended to mean Cytochrome P, and more specifically Cytochrome P 450, the major phase I metabolizing enzyme of the liver constituting of many different isoenzymes, such as CYP1A1, CYP1A2, CYP1B1, CYP2A6/2A7/2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7 and CYP7A1.
- As used herein, the term “GST” is intended to mean glutathione transferase, and examples of subtypes thereof are GST A1-1, GST M1-1, and GST P1-1.
- As used herein the term “UGT” is intended to mean uridine diphosphoglucuronosyltransferase, which is a group of liver enzymes catalyzing glucuronidation activities
- As used herein, the term “Cytochrome P450 reductase” (also known as CPR) is intended to mean a protein which physiological function is the reduction of Cytochrome P450 enzymes by electron transfer and which is therefore required for Cyotchrome P450 enzyme-mediated reactions.
- By the term “functional drug metabolising enzymes” is intended to mean functional enzymes belonging to the phase I and phase II enzymes that perform chemical modifications of xenobiotics and drugs, so called drug or xenobiotic metabolism.
- As used herein, the term “functional activity” means effective measurable hepatic cell function, such as a measurable transportation of drugs for drug transporters and a measurable metabolism of enzymes for the Cytochrome P450s (CYPs), commonly detected in primary human hepatocytes.
- As used herein, the term “extraembryonic endoderm (E×E)” is intended to mean the differentiated endodermal cells that, as to the opposite of the definitive endoderm, will constitute the compartments outside the embryo in the human development, such as the yolk sac.
- As used herein, the term “AAT” is intended to mean the liver marker alpha-anti-trypsin.
- As used herein, the term “
Alcohol dehydrogenase 1” is intended to mean a type of dehydrogenase enzyme that facilitates the interconversion between alcohols and aldehydes or ketones with the reduction of NAD+ to NADH.Alcohol dehydrogenase 1 serves to break down alcohols which could otherwise be toxic. - As used herein, the term “AFP” is intended to mean the liver marker alpha-fetoprotein. As used herein, the term “BSEP” is intended to mean the bile transporter bile salt export pump.
- As used herein, the term “CK” is intended to mean the liver marker cytokeratin (used interchangeably) with different subtypes such as Cytokeratin 18 (CK18/KRT18), Cytokeratin 19 (CK19/KRT19), Cytokeratin 8 (CK8) and Cytokeratin 7 (CK7).
- As used herein, the term “FGF” means fibroblast growth factor, preferably of human and/or recombinant origin, and subtypes belonging thereto are e.g. “bFGF” (means basic fibroblast growth factor, sometimes also referred to as FGF2) and FGF4. “aFGF” means acidic fibroblast growth factor (sometimes also referred to as FGF1).
- As used herein, the term “BMP” means Bone Morphogenic Protein, preferably of human and/or recombinant origin, and subtypes belonging thereto are e.g. BMP4 and BMP2.
- As used herein, the term “HGF” means Hepatocyte Growth Factor, preferably of human and/or recombinant origin.
- As used herein the “HNF3beta”, or “HNF3b”, used interchangeably are intended to mean hepatocyte nuclear factor 3, a transcription factor regulating gene expression in endodermal derived tissue, e.g. the liver, pancreatic islets, and adipocytes. HNF3beta may sometimes also be referred to as HNF3b or Fox2A the latter name originating from the transcription factor being a member of Forkhead box transcription factors family.
- As used herein the term “OCT-1” is intended to mean
organic cation transporter 1. OCT-1 is a major hepatic transporter that mediates the uptake of many organic cations from the blood into the liver where the compounds may be metabolized or secreted into the bile. - As used herein the term “MDR” is intended to mean multi-drug resistance transporter.
MDR 1 and 3 are members of the ATP-binding cassette (ABC) family of transporters and both are drug efflux transporters.MDR 1 is important in regulating the traffic of drugs, peptides and xenobiotics into the body and in protecting the body against xenobiotic insults and drug toxicity, while MDR 3 is essential for phospholipid secretion into bile. - As used herein the term “Activin” is intended to mean a TGF-beta family member that exhibits a wide range of biological activities including regulation of cellular proliferation and differentiation such as “Activin A” or “Activin B”. Activin belongs to the common TGF-beta superfamiliy of ligands.
- As used herein the term “ROCKInhibitor” is intended to mean a small molecule inhibitor of the ROCK Rho-kinase, such as Y-27632 or Fasudil.
- As used herein the term “xeno-free” is intended to mean complete circumvention of direct or in-direct exposure to non-human animal components.
- As used herein, the term “hepatocellular toxicity” indicates cellular responses such as necrotic toxicity, apoptosis, mitochondrial toxicity, phospholipidosis, steatosis and bile acid transport.
- One aspect of the present invention relates to a method for differentiating human pluripotent stem cells (hPS) or hepatocyte precursor cells into mature hepatocyte or hepatocyte-like cells, the method comprising the steps:
-
- i) Seeding of hPS or hepatocyte precursor cells on a 2-dimensional surface to initiate differentiation
- ii) Transferring the initially differentiated cells of step i) to a 3-dimensional (3D) scaffold for further differentiation and maturation.
- The cells may be seeded at a higher density on the 3D scaffolds than on the 2D cultures, such as threefold higher or fivefold higher or tenfold higher however. Further, Rho kinase (rock) inhibitors may be added and/or the method can be performed under feeder-free or xeno-free conditions.
- The cells used in the methods according to present invention may be xeno-free cells, such as a xeno-free hPS cell line or cells derived from a xeno-free hPS cell line, or the cells may be human embryonic stem (hES) cells or induced pluripotent stem (iPS) cells. The hepatocyte precursor cells according to present invention may be definitive endoderm (DE) cells or not and may have characteristics of fetal endoderm or hepatic endoderm.
- The transition from step i) and ii, i.e. the transfer of the cells obtained in step i) are transferred to a 3D-scaffold (step ii) may be performed after 2 to 25 days, such as 4 to 15 days.
- The 3 dimensional scaffold may be chosen from one of the following types: i) a porous alginate sponge, ii) a biodegradable poly (urethaneurea) (PUUR) polymer, iii) an emulsion-templated polystyrene, iv) a synthetic nanofibrillar composite v) a microwell device with at least one non-vertical side-wall, vi) a porous sponge fabricated from Poly (L-lactic Acid) [PLLA] or the 3 dimensional scaffold may be of another suitable type.
- The porous alginate sponge may have a pore size of 50-200 μM, whereas the pore size of the emulsion templated polystyrene scaffold is in the range of 0.1-1000 μM, such as 15-45 μM.
- Further, present invention relates to a method as described above, wherein the 3D-scaffold is uncoated. In another aspect, the 3D-scaffold is pre-coated e.g. with one or more extracellular matrix components. Examples of such extracellular matrix components comprise: gelatine, laminin, fibronectin, collagen, polylysine, vitronectin, hyaluronic acid, hyaluronan hydrogels, silk fibroin, chitosan or a composite of any of the forementioned.
- The 3D-scaffold of present invention may be contained within a suitable culture vessel, such as a multiwell plate including but not limited to a 6-well plate, a 12-well plate, a 24-well plate, a 48-well plate, a 96-well plate, a 384-well plate, a 1536-well plate or other suitable cell culture vessel.
- Hence, the invention detailed herein comprises a process used to improve the differentiation of hPS cells towards cells having a more hepatic phenotype or cells ultimately having a partially or fully mature hepatic phenotype, this process requiring the cells to be initially cultured on a 2-dimensional culture surface before being transferred one of six possible 3-dimensional scaffolds. This improvement in hepatic phenotype is independent of any particular cell culture medium composition (see
FIG. 9 for details of cell culture protocols employed). - Based on gene expression and metabolic studies, the inventors of the present invention have found that 3D scaffolds provide a better environment for the maturation and further differentiation of hPS-derived hepatocyte cells or hepatocyte progenitors compared to more traditional 2D substrates (
FIGS. 1-6 ). Further, the inventors have found a further effect when culturing the cells on a 2D surface before seeding the cells in the 3D environment. - This can be seen by comparing the expression of several hepatic marker genes such as Cyp2C9, Albumin, Cyp3A4, and UGT2B7 which are all expressed more highly in cells cultured on 3D scaffolds than on 2D surfaces, regardless of cell line, matrix coating, days in culture or scaffold chosen. Specifically, a large number of hepatic transporters (BSEP, FABP1, MRP2, NTCP, OATP2, OCT1) are expressed in much higher levels when cultured in 3D indicating more mature and functional hepatocytes. This can be seen for a range of different scaffold types including topographical scaffolds such as Ultraweb (
FIG. 3 ) and Aggrewell (FIG. 5 ), porous sponge types such as AlgiMatrix (FIG. 2 ) and Poly-L-lysine (FIG. 6 ) and on synthetic polymer-based scaffolds such as Artelon (FIG. 1 ) and Alvatex (FIG. 4 ). - The 3D scaffold may be pre-coated with a matrix component to better resemble in vivo microenvironment normally encountered by hepatocytes. Specifically, the matrix components gelatine and matrigel have been shown to improve the expression levels of some hepatic markers when used in conjunction with the scaffolds. Expression of several markers (TAT, CYP2C9, OATP2,) is higher on matrigel-coated Artelon (Artimplant) compared to uncoated (
FIG. 1 C & E;FIG. 1 A & D). A number of markers (TAT and UGT2B7) are significantly more highly expressed on matrigel-coated Alvatex compared to uncoated (FIG. 4 F & G, analysed at day 18) and this is also true for several other markers (such as TAT, UGT2B7) which are expressed to a higher degree on gelatine-coated Alvatex compared to uncoated (FIG. 4 E & G). This particular embodiment of the invention can be optionally applied depending upon which markers it is desired to see expressed to a high degree. Since expression of a particular set of markers will imply a certain phenotype or stage of hepatic lineage, application of this aspect of the invention may allow a finer degree of control over the functionality of the hepatocytes generated. An extension of this aspect could be the addition of one or more different cell types to the hPS cells or hPS-derived hepatic progenitors which are seeded onto the 3D scaffolds, allowing co-culturing of cell lines on the 3D scaffolds. - Notably, the cells may be seeded at different relative densities on the 3D scaffolds. The relative density may be a standard ×1 density (i.e. the same density as cells seeded on the 2D control surface) or a three-fold higher initial density (designated as x3) or a ten-fold higher density or any density there in between.
FIG. 1 H & I show that expression of markers OATP2, OCT1 and TAT is higher in cells seeded at the lower x1 initial density when using uncoated Artelon (Artimplant). Expression of certain markers (e.g. CYP7A1) are also lower on cells seeded at ×3 on uncoated Alvatex compared to cells seeded at ×1, (FIGS. 4 N & O) but other markers (such as OCT1) had higher expression in cells seeded at ×3 on uncoated Alvatex (FIG. 4 I & K). Therefore application of this particular embodiment is again dependent upon the desired phenotype of the hepatocyte cells which is required by the user. - To permit control of the differentiation, the stage of differentiation at which the cells are seeded on the 3D scaffolds is relevant, i.e. cultured for longer being of a more mature phenotype before seeding in 3D scaffold. The hPS cells can be seeded in the scaffolds at several different stages of differentiation, e.g. as undifferentiated cells (day 0) or after treatment with activin A for definitive endoderm-induction (day 4-7) or as hepatic precursors (
day FIG. 11 ) or the more advanced hepatocyte precursor (FIG. 12 ), based on expression of defined marker genes characteristic for both stages. Differences are readily observed on cells cultured on Artelon (Artimplant), where for example, expression levels of OCT1 are almost double in cells seeded at 14 days compared with those seeded at day 11 (FIG. 1 F & H). In contrast to this, levels of OATP2 are decreased in cells seeded at 14 days on Artelon (Artimplant) compared to those seeded day 11 (FIG. 1 J & M). This trend can also be seen in cells cultured on Alvatex, where again the 14 day old seeded cells possess lower expression levels of OATP2 than the 11 day cells, possibly indicating that OATP2 is a marker for more immature hepatocyte phenotypes (FIG. 4 I & J). In a similar manner it can be seen that levels of OCT1 are also higher in cells seeded when younger (day 11) than in more mature (day 14), (FIG. 4 N & P). Thus length of cell culture and differentiation time is an important factor of this invention in terms of controlling final phenotype of the cells produced and can be altered accordingly. As outlined inFIG. 9 , and in the table below, the duration of culturing and the media compositions may be adjusted to optimize the maturity and developmental stage of the cells obtained by the methods disclosed herein. A related aspect concerns the differentiation regime to which the cells are subjected prior to seeding onto the scaffolds, as detailed in Example 2, in particular whether the cells are exposed to medium containing an inhibitor of the Rho-kinase ROCK, such an inhibitor being used to improve survival and re-attachment of cells after passaging and seeding both in the 2D and 3D stages. - An improvement in function and metabolic activity has been observed in the hepatocytes seeded onto 3D scaffolds compared to those grown on conventional 2D surfaces. hESC-derived hepatocytes, matured in 3D scaffolds according to Example 6, showed greater induction of CYP activity than 2D control cultures (
FIGS. 7 & 8 , 10) when exposed to the drugs Phenacetin (APAP), Midazolam or Diclofenac, with the Alvatex scaffold showing the greater induction than the Ultraweb. A further examination of cells cultured on Alvatex (Reinnervate) showed that at both 23 and 29 days after initiating differentiation, those cells had a much greater metabolic activity than cells cultured on 2D surfaces as measured by CYP2C9 activity. CYP2C9 activity was already high in cells cultured on 3D surfaces but was also observed to be elevated when cells were treated with diclophenac (FIG. 8 ). This again shows that hepatocytes which are differentiated on 3D scaffolds have a superior metabolic hepatocytoc function when compared to 2D cultured cells. These results are borne out by the findings that levels of the crucial hepatic marker CYP3A are also higher in cells cultured on matrigel-coated Alvatex (Reinnervate) and slightly higher in cells cultured on Ultraweb compared to the 2D control when cells were assayed for metabolic breakdown products of the drug Midazolam (FIG. 8 ). Thus the invention has shown several examples of improved hepatic metabolic activity in cells cultured on 3D scaffolds. - Hence as discussed above an aspect of the present invention relates to a method wherein the hepatocyte cells or hepatocyte progenitors display elevated metabolic activity as shown by increased expression of one or more CYP markers, such as CYP2C9 or CYP3A and/or elevated levels of hepatocyte-associated genetic markers selected from the list comprising: CYP1A1, CYP1A2, CYP3A4, CYP2C9, CYP3A7, CYP7A1, MRP2, Albumin, UGT2B7, AAT, TAT.
- Further, an aspect of present invention relates to a method wherein the hepatocyte cells or hepatocyte progenitors display increased expression of one or more hepatic-associated transporter proteins such as BSEP, FABP1, MRP2, NTCP, OATP2, OCT1.
- The present method may as discussed above, stimulate that the proportion of hepatocytes or hepatocyte progenitors compared to non-hepatocyte cells is greater than 5%, such as 10%, such as 20%, such as 30%, such as 40%, such as 50%, such as 60%, such as 70%, such as 80%, such as 90%, such as 100%.
- A method according to any of the preceding claims wherein the hepatocytes or hepatocyte progenitors are co-cultured on the 3D scaffolds with at least one other cell type chosen from, but not limited to: stellate hepatic cells, hepatic immune (Kuppfer) cells, hepatic endothelial cells, biliary epithelial cells or fibroblasts
- Accordingly and as discussed above, an aspect of the present invention relates to an hPS derived hepatocyte cell or hepatocyte progenitor cell or a composition comprising an hPS derived hepatocyte cell or hepatocyte progenitor cell obtainable by a method described herein. Further aspects of the present invention relates to the use an hPS derived hepatocyte cell or hepatocyte progenitor cell or a composition comprising an hPS derived hepatocyte cell or hepatocyte progenitor cell obtained by the methods herein in therapy, regenerative medicine, for drug screening, toxicity testing or drug delivery.
- The composition may further comprise a 3D scaffold, such as but not limited to a porous alginate sponge, a biodegradable poly(urethaneurea) (PUUR) polymer, an emulsion-templated polystyrene or a synthetic nanofibrillar composite.
- Starting Material for Hepatocytes Derived from Human Pluripotent Stem Cells
- All hPS cells (as defined above) can be used as staring material for this invention. For the examples below hepatocyte-like cells were derived in vitro from undifferentiated human embryonic stem cells (hESC) cultured on mEF cells (Heins, N. et al. 2004, Stem Cells). The cell lines used for this experiment could be, but is not limited to the hES cell line SA002, SA121, SA181, SA461 (Cellartis AB, Göteborg, Sweden, http://www.cellartis.com) and they can be propagated as described Heins, N et al. 2004. These cell lines are listed in the NIH stem cell registry, the UK Stem Cell bank and the European hESC registry and are available on request. Along with hPS obtained from hESC, hPS obtained from hiPS (induced pluripotent stem cells) have been used for the derivation of hepatocytes for the examples of this invention. In this case, “hiPS-HEP” is intended to mean a cell type derived from induced pluripotent stem cells which is expressing mature hepatic markers such as Albumin, CYP3A4, UGT2B7, OATP-2, ADH1A, UGT1A6, CYP2C9, CYP2C19 and CYP2D6 (see also “Definitions”). Use of xeno-free iPS cells or a xeno-free derived hES cell line such as SA611 (Cellartis AB, Goteborg, Sweden, http://www.cellartis.com) could optionally allow the entire invention to be used under xeno-free conditions to produce a xeno-free cell product.
- Derivation of Hepatocytes from Human Pluripotent Stem Cells Using 3D Scaffolds.
- Hepatocytes were derived from both hES cells and human hiPS cells according to the protocols a-e, as detailed below. Before start of differentiation, the cultures were washed twice with PBS. The different media (Table 1) were prepared freshly and added from
day 0 and afterwards according to the protocol overview. Medium was changed every day or every second day during the initial differentiation (ID) step, and every second or every third day afterwards. Only one cell line was used for each experiment, but optionally a second (or more) cell line could be added when the initial cell line is seeded onto the 3D scaffolds allowing co-culturing of the cells. - 2D cultures were seeded on matrigel coated culture vessels, except in experiment 114 and 116 when 2D cultures were seeded on gelatin coated culture vessels. 2D cultures were seeded in 150.000-200.000 cells/cm2.
- The table below shows an overview of the different experiments, which cell lines were used as starting material, the variants of differentiation protocol as outlined in
FIG. 9 , time of the differentiation protocol when the cells were seeded in 3D scaffolds, time of differentiation when cells were analyzed, and whether 10 mM ROCKInhibitor was added or not to the medium at time of seeding in scaffolds (see alsoFIG. 9 for schematic details of protocols employed): -
Exper- Protocol iment (see Seeded ROCK- no. FIG. 7) Cell lines in 3D Analyzed Inhibitor Exp083 e SA461FF Day 15 Day 30− Exp088 d SA002ECD Day 14 Day 24− Exp089 d SA002ECD Day 14 Day 24− Exp098 c SA002DEF Day 5 Day 25− SA181DEF SA461DEF Exp104 b SA121DEF Day 4 Day 18 &− 22 Exp112 a SA121DEF — Day 7− SA181DEF Exp113 a SA181DEF Day 11&14 Day 24+ Exp114 a SA181DEF Day 9, 11 Day 24+ & 14 Exp116 a SA121DEF Day 13 Day 24+ Exp118 a SA181DEF Day 0, 7, 11 Day 24+ Exp119 a SA121DEF Day 0, 7, 11 Day 24+ SA181DEF Exp120 a SA181DEF Day 0, 7, 11 Day 24+ Exp122 a SA121DEF — Day 7− Exp139 g SA121DEF Day 7 Day 24− Exp140 g SA121DEF Day 7 Day 24− Exp148 g SA121DEF Day 7 Day 24− Exp153 i SA121DEF Day 4 Day 25− Exp169a h IMR90 Day 7 Day 7 and+ day 32Exp169b f IMR90 Day 4 Day 4 and+ day 29Exp172 f IMR90 Day 7 Day 29+ Exp175 g SA121DEF Day 11 Day 25+ Exp175 f SA181DEF Day 11 Day 25+ Exp177 g SA121 — Day 11− Exp177 h SA181 — Day 11− CYP3A g SA121 Day 7 Day 24− induction CYP3A h SA181 Day 7 Day 24+ induction - Scaffolds and Matrix Coatings Used in the Studies
- Artelon (Artimplant); <150 μm poresize, formatted for 48 well plates, kindly provided by Artelon (Artimplant) (Västra Frölunda, Sweden) [see WO0035507; also Blumenthal, B. et al. (2010)]
- Alvatex; size for 48 wells, kindly provided by Stefan Przyborski ReInnervate, (Durham, UK) (see WO07125288, WO10038013)
- AlgiMatrix; Invritogen/Gibco, cat no 12684, lot nr 731950, 96 wells (exp088+089) [see WO08112904; also Shapiro, L & Cohen, S. (1997)]
- UltraWeb; Corning, cat no 3873xx, lot no 09207043, 96 wells (exp088+089) [see WO09032117; WO10060066, also Piryaei, A. et al. (2010)]
- Aggrewell; Stem Cell Technologies, cat 27865, approx. 300 microwells, [see WO2008106771]
- HAC/Porocell; (HacBiomed); [Cell Transplant. 1997 September-October; 6(5):463-8.
- Highly porous polymer matrices as a three-dimensional culture system for hepatocytes.
- Kaufmann P M, Heimrath S, Kim B S, Mooney D J.]
- Preparation of 3D Scaffolds and 2D Culture Dishes Before Use:
- The Artelon (Artimplant) and Alvatex scaffolds were soaked in 70% EtOH, the EtOH was removed and the scaffolds were washed twice with DPBS.
- Matrigel: Growth factor reduced matrigel from BD, Lot no 0934 was diluted to 0.016 mg/ml in DPBS, and added to scaffolds and 2D culture dishes, incubated at RT for at least 1 h RT, then matrigel was removed immediately before use.
- Gelatine: gelatin from production was added to the scaffolds and/or 2D culture dishes, incubated at RT for at least 30 min, then the gelatin was removed immediately before use.
- Passaging and Maintenance of hES Cell Cultures
- Media was removed from the cell cultures, and the cultures were washed 2× in DPBS−/− (37° C., 0.5 ml/cm2). TrypLE Select was added (RT, 0.1 ml/cm2) and incubated at 37° C. (4-5 min for undifferentiated cells or cells after Activin A treatment, 10-45 minute for cells at progenitor stage). The cells were then detached by flushing the cells with a p1000. VitroHES was added (37° C., 0.1 ml/cm2) and the cell suspension was transferred to centrifuge tubes and centrifuged at 330×
g 5 min at RT. The cell pellet was resuspended in culture medium, cells were counted and diluted to appropriate seeding suspension. In some experiments, 10 mM Rock inhibitor was added to the culture medium at day of seeding (exp113, 114, 116, 118, 119, 120) - Gene Expression Analysis of hESC-Derived Hepatocytes Cultured on 3D Scaffolds.
- hESC-HEP were derived from cell-line SA002, SA121, SA181, SA46 cultured from the DEF cultures system or SA002 cultures on mEF-layer as indicated in figure legends.
- Total RNA was collected and isolated from the hES-HEP cultures at
day multi-drug residence protein 2, also called ABCC2), BSEP (bile salt export pump), NTCP (solute carrier, sodium/bile acid cotransporter) OCT1 (solute carrier, organic cation transporter), OATP2 (solute carrier, organic anion transporter), FABP1 (Fatty acid binding protein involved in fatty acid uptake, transport, and metabolism), and general hepatic markers; AAT (alpha-1 antitrypsin), ADH1A (alcohol dehydrogenase 1A) ALB (albumin) and TAT (tyrosine-amino transferas). All data was normalised to the house-keeping gene CREBBP, except when other is indicated. Data is presented as fold change of 2D controls, except when other is indicated. - Data is presented in
FIGS. 1-4 and shows that hepatic genes are expressed at higher levels in hESC-HEP when cultured in 3D compared to 2D. The improved expression levels of the other hepatic markers in 3D cultures are supporting the finding that 3D cultures are important in hepatic differentiation of hESC. - CYP Assay
- At
day Streptomycin 2 mM L-Glutamine and 25 mM Hepes. A volume of 100 μl diluted substrates were added per cm2 of the well surface (e.g. 75 ul pr 48 wells). hESC derived hepatocyte cultures with substrates were incubated over night. After 16 h, medium was collected and subsequently, centrifuged at 10 000 g, 4° C. for 20 min. Samples were analysed by Liquid chromatography-mass spectrometry (LC-MS) LCMS for presence of the metabolite Paracetamol, 4-OH-diclophenac and 1-0H Midazolam, biotransformed by the cytochrome p450 enzymes Cyp1A2, 1A1 (Phenacetin) Cyp 2C9, 2C8 (Diclophenac) and Cyp 3A4, 3A5 (Midazolam). - Improved Cyp2C9 Activity and Improved Induction of CYP2C9 Activity in Cells Cultured in ReInnervate Scaffolds
- Cell line SA461 (Cellartis AB) was cultured and differentiated according to conditions in Examples 1 and 2, experiment 083 and then according to the scheme below:
-
D0 Start of differentiation Medium D15 2D 24 well Relnn 24 2D 24well Relnn 24 Transfer to 3D and 2D 7 wells well 7 wells well 7 wells 7 wells D16 50% medium change, M5 D17 50% medium change, M D18 50% medium change, M5 D19 — D20 50% medium change, M5 D21 50% medium change, M6 D22 Induction Induction induction D23 Activity Activity 100% medium change M6 assay start assay start D24 Activity Activity 50% medium change, M6 assay assay finish, finish, Resazurin Resazurin & RNA & RNA D25 50% medium change, M6 D26 50% medium change, M6 D27 — D28 Induction Induction 100% medium change M6 D29 Activity Activity 100%, 2.5 ml assay start assay start D30 Activity Activity 100% assay finish, assay Resazurin & finish, RNA Resazurin & RNA - Growth medium composition as applied above:
-
M5 M6 Spin down medium Seeding medium WME + SQ − WME + SQ − 50% plating media Seeding Media GA1000 GA1000 from InVitroTech 50% Plating (+0.1% PEST) (+0.1% PEST) 2 ng/ ml bFGF 10 ng/ml OsM 50% WE media from (0.2 μl (1 μl InVitroTech stock/ml) stock/ml) 20 ng/ml HGF 0.1 μM DexM 50% M5 (2 μl (1.6 μl stock/ml) stock/ml) 2 ng/ml bFGF (0.2 μl stock/ml) 2 ng/ml HGF (0.2 μl stock/ml) - Differentiation was carried out up to
day 15, and onDay 15 scaffolds were cut in small circles to fit into 24 well plates. The Alvatex (Relnnervate) scaffolds were washed with 70% EtOH, the EtOH was removed and the wells were washed twice with PBS+/+. Matrigel: GFR matrigel Lot no 6741 diluted to 0.016 mg/ml in DPBS, and added to scaffolds, 500 ul pr well and pr scaffold. The scaffolds were incubated for ˜1 hour RT with the matrigel. The matrigel was removed immediately before use. - The aim was to seed in 2D wells with a split ratio of 1.5:1. In Alvatex (ReInnervate), 5 times as many cells were seeded, which is a split ratio of 7.5:1. Starting out with 27 wells of 9.6 cm2, that is 260 cm2. For seeding 100 ul pr cm2 in the Alvatex (ReInnervate) scaffold the cells were resuspended in (260/7.5×0.1=34.6) 3.46 ml.
- 27 wells of cells were washed 1× in DBPS+/+ and 2 ml Tryple Select was added pr well,
incubation 23 min at 37 C. The Spin down Medium was added and cells were flushed to detach them. Cells collected and spun 5min 400×g. Resuspended in 3.46 ml Seeding Media. 200 ul of this suspension was seeded pr Alvatex (ReInnervate) scaffold. 600 ul of the suspension was diluted 5×, and of this, 200 ul wasseeded pr 2D well. Then medium was added to a total of 800 ul pr well in all wells. - Counting cells: 27.9×106 cells/ml (87% viability), 3.46 ml total, 96×106 cells total.
-
Well Area/ # wells Total Seeding Cells/well Total medium Scaffold type well seeded area volume/well seeded volume per well Alvatex 24 2 cm 214 28 cm 2200 μl 5.6 × 106 0.8 (ReInnervate) 5× 2D 24 2 cm 214 28 cm 2200 μl 1.1 × 106 0.8 - Induction:
- Cells were induced with 1 mM Phenobarbital, 10 μM dexamethasone and 5 μM β-naphthoflavone.
- To obtain these
solutions 100 μl 64 mM dexamethasone solution was diluted with 540 μl DMSO to obtain a 10 mM dexamethasone solution 11.4 mg β-naphthoflavone was dissolved in 8.446 ml DMSO to obtain a 5 mM solution 1M Phenobarbital was diluted 1:1 with PBS - To 35 ml M6 (w/o Dex) 35
μl 10 mM dex, 35μl 5 mM β-naphthoflavone and 70 μl 0.5M Phenobarbital. - Control medium (non-induced medium) did not contain any DMSO to be able to compare the enzyme activity with the baseline enzyme activity.
- To each well, either induction or control medium was added (400 ul/
well 2D cultures, 2000 ul/well in ReInnevate scaffolds) and the plate was incubated 24 h. - Activity Assay:
- After 24 hours of induction, all wells were washed 2× in DPBS+/+ and activity assay medium was added, 200 ul/well in 2D controls and 1000 ul/well in ReInnervate scaffolds. Activity assay medium: a protein-free medium without phenol red consisting of WE with 0.1% PEST, 2 mM L-Glutamine, 25 mm HEPES and 26 uM Phenacetin, 3 uM Midazolam and 9 uM Diclophenac.
- After 16 hours incubation at 37 C, the medium was transferred to eppendorf tubes and spun down for 20 min at 4° C. and 10000 g. Supernatants were analyzed by HPLC for the presence of OH-Diclophenac, which is the metabolite of Diclophenac.
- Verification that Cells have Differentiated into Embryonic Endoderm or Hepatic Precursors at the Time of Seeding in the Scaffolds
- The protocols used for differentiation towards hepatocytes were analyzed for the formation of embryonic endoderm cells after the “endoderm induction” step, cells cultured according to protocol a) (
FIG. 11 ). Atday 7 in the differentiation protocol, cells were harvested for RNA and analyzed by Real-time PCR and compared to the undifferentiated cells from start of the experiment (day 0). It was shown that the differentiation protocols generated cells expressing embryonic endoderm markers (FOXA2, SOX17, HHEX, CXCR4, CER1). Furthermore, it was verified that markers (Nanog and OCT4) for undifferentiated cells was down-regulated compared to the undifferentiated starting material. Additionally, it was checked that cells were expressing extra-embryonic endoderm markers (Sox7 and CDX2), as these genes were not increased during the endoderm induction. A similar method was employed to test that cells which were being seeded onto scaffolds as “hepatic precursors” did indeed possess this phenotype (FIG. 12 ). -
FIG. 1 . - hESC-Derived Hepatocytes Cultured on Artelon (Artimplant))
- Relative expression levels of hepatic-markers on hESC-derived hepatocytes cultured either on 2D culture or 3D Artelon (Artimplant) scaffold. Artelon (Artimplant) is either uncoated or coated with matrix (Matrigel or gelatine) and cells seeded either at x1 density or ×3 density. Figure shows three independent cell lines (SA461, SA002, SA181) with cells cultured on scaffolds for either 0, 5, 11, 12, 14 or 15 days according to experiment numbers shown, protocols a) and c)
-
FIG. 2 a. - hESC Derived Hepatocytes on AlgiMatrix.
- Relative expression of hepatic markers on hESC-derived hepatocytes cultured either on 2D or 3D AlgiMatrix scaffold. Figures show two independent cell lines (SA002 and SA121) with cells cultured on scaffolds for either 14 or 13 days respectively, protocol d)
-
FIG. 2 b. - iPS-Derived Hepatocytes on AlgiMatrix.
- Relative expression of hepatic markers on iPS-derived hepatocytes cultured either in 2D or on 3D AlgiMatrix scaffold. Cells were differentiated for 7 days prior to seeding on scaffold and analysed after 32 days culture; protocol h (Exp169a) or f (Exp169b)
-
FIG. 3 . - hESC Derived Hepatocytes on Ultra Web.
- Relative expression of hepatic markers on hESC-derived hepatocytes cultured either on 2D or 3D Ultraweb scaffold. Ultraweb is either uncoated or coated with matrix (Matrigel or gelatine). Figures show four independent cell lines (SA002, SA461, SAl21 and SA181) with cells cultured on scaffolds for either 4, 5, 7 or 14 days, protocols a), b), c), d)
-
FIG. 4 a. - hESC Derived Hepatocytes on Alvatex. (Reinnervate)
- Relative expression levels of hepatic-markers on hESC-derived hepatocytes cultured either on 2D culture or 3D Alvatex (Reinnervate) scaffold. Alvatex is either uncoated or coated with matrix (Matrigel or gelatine) and cells seeded either at ×1 density or ×3 density. Figure shows four independent cell lines (SA461, SA002, SA181 and SA121) with cells cultured on scaffolds for either 0, 4, 9, 11, 13 or 14 days according to experiment numbers shown, protocols a), c), d)
-
FIG. 4 b. - iPS Derived Hepatocytes on Alvatex. (Reinnervate)
- Relative expression levels of hepatic-markers on iPS-derived hepatocytes cultured either on 2D culture or 3D Alvatex (Reinnervate) scaffold. Alvatex is either uncoated or coated with matrix (Matrigel or Fibronectin) and cells seeded after 7
days 2D culture at x6 density that of 2D cultures from which cells were harvested. Figure shows one independent iPS line (IMR90) with cells cultured on scaffolds for up to 29 days before analysis; culture protocol f. -
FIG. 5 a - hESC-Derived Hepatocytes on Aggrewell
- Relative expression levels of hepatic-markers on hESC-derived hepatocytes cultured either on 2D culture or 3D Aggrewell scaffold. Aggrewell is coated with matrix (Fibronectin) prior to seeding with cells cultured in 2D for 11 days; culturing according to protocol f) and cells seeded at either 100 or 200 aggregates per well. Figure shows one independent hESC line (SA181) with cells cultured on scaffolds for up to 25 days before analysis.
-
FIG. 5 b - iPS Derived Hepatocytes on Aggrewell
- Relative expression levels of hepatic markers on iPS-derived hepatocytes cultured either on 2D culture or 3D Aggrewell scaffold. Aggrewell is coated with matrix (Fibronectin) prior to seeding with cells cultured in 2D for 7 days. Figure shows one independent iPS line (IMR90) with cells cultured on scaffolds for up to 29 days before analysis; culture protocol i)
-
FIG. 6 - Relative expression of hepatic markers of hESC-derived hepatocytes cultured on Poly-l-
lysine 3D scaffold (HAC). Cells were partially differentiated on 2D for 7 days prior to seeding and cultured untilday 24 before analysis of marker expression; culture protocol g). -
FIG. 7 . - CYP Activities of hESC-Derived Hepatocytes in 3D Scaffolds. 3D Scaffold Left=Alvatex, 3D Scaffold Right=Ultra Web.
Experiment 24, SA001 ECD. - Figure shows relative CYP activity of hESC-derived hepatocytes cultured either on Alvatex, Ultraweb or 2D control, with cells treated with either APAP, Midazolam or Diclofenac to induce CYP response and mimic hepatic metabolic activity.
-
FIG. 8 . - CYP Induction in hESC Derived Hepatocytes Cultured in Either
Conventional 2D Culture Plates or Alvatex Scaffolds. - Figures show CYP response in hESC-derived hepatocytes cultured either on Alvatex (Reinnervate) or 2D control, cells induced with Diclofenac to mimic hepatic liver activity. Activity assay performed at
day 23 andday 29 as indicated. -
FIG. 9 . - Schematic of Differentiation Protocols Used to Differentiate hPS Cells to Hepatocytes.
- Protocols a-e and respective experiment numbers together with duration of each experiment
- Protocol a: (
exp 113, 114, 118, 119, 120). - 2 Days ID1, 5 days ID2, 2 days P1, 2 days VH1, 5 days VH2, 8 days M1
- Protocol b: (Exp104)
- 4 days ID3, 3 days P1, 2 days VH1, 3 days VH2, 2 days VH2B, 4 days or 8 days M2 (for cell cultures analyzed
day 18 and day22 respectively) - Protocol c: (exp098)
- 5 days ID3, 3 days P1, 7 days VH1, 10 days M3
- Protocol d: (exp088, 089)
- 2 days ID1, 2 days ID2, 3 days P1, 7 days VH1, 10 days of M4
- Protocol e: (exp083)
- 1 day ID4, 5 days ID5, 6 days P1, 8 days M5, 15 days M6.
- Protocol f: (exp169b, 172, 175SA181)
- 1 day ID1, 1 day ID6, 5 days ID2, 7 days VH1, then M1 till end of experiment
- Protocol g: (exp139, 140, 148, 175SA121, 177SA121, CYP3A induction)
- 1 day ID7, 1 day ID8, 5 days ID9, 7 days VH1, then M1 till end of experiment
- Protocol h: (exp169a, 177SA181, CYP3A induction)
- 1 day ID7, 1 day ID1, 5 days ID2, 7 days VH1, then M1 till end of experiment
- Protocol i: (exp153)
- 1 day ID10, 1 day ID11, 2 days ID3, 7 days VH1, then M1 till end of experiment Detailed growth media composition used in protocols a to e
-
Initial differentiation (ID) ID1 ID2 ID3 ID4 RPMI 1640 (+ RPMI 1640 (+ RPMI 1640 (+ 0.1% Advanced RPMI 0.1% PEST, + 1% 0.1% PEST + 1% PEST + 1% 1640 (+ 0.1% PEST + Glutamax) Glutamax) Glutamax) 1% Glutamax) 1 × B27 1 × B27 1 × B27 100 ng/ ml Activin A 100 ng/ ml Activin A 100 ng/ ml Activin A 100 ng/ml Activin A 0.5 ng/ ml bFGF 1 mM NaB 0.5 mM NaB ID5 ID6 ID7 ID8 Advanced RPMI RPMI 1640 (+ mDEF RPMI 1640 (+ 0.1% 1640 (+ 0.1% 0.1% PEST, + 1% 3 μM Chiron PEST, + 1% PEST + 1% Glutamax) Glutamax) Glutamax) 1 × B27 1 × B27 100 ng/ ml Activin A 100 ng/ml Activin A 50 ng/ml Activin A 0.5 ng/ ml bFGF 1 mM NaB 1 mM NaB 0.2% FCS 3 uM Chiron ID9 ID10 RPMI 1640 (+ RPMI 1640 (+ 0.1% PEST + 1% 0.1% PEST, + 1% Glutamax) Glutamax) 1 × B27 3 uM Chiron 50 ng/ml Activin A 0.5 mM NaB -
Hepatic Progenitor Media P1 VH1 VH2 VH2B RPMI A (+ 0.1% VitroHES VitroHES VitroHES PEST, + 1% 1 % DMSO 2 % DMSO 2% DMSO Glutamax) 1.4 μM BIO 100 ng/ ml aFGF 5 ng/ml bFGF 50 ng/ ml BMP2 200 ng/ml BMP4 0.2% FBS -
Maturation Media M1 M2 M3 M4 WME + SQ As M4 As M4 but WME + SQ (−GA1000) supplemented using MEF (−GA1000) (+1% Glutamax + with conditioned (+1% Glutamax + 0.1% PEST) 1.4 μM BIO WME + SQ 0.1% PEST) 10 ng/ml OsM (−GA1000) + 10 ng/ml OsM 0.1 μM DexM 1% Glutamax + 0.1 μM DexM 20 ng/ml HGF 0.1 % PEST 2 ng/ml bFGF 0.5% DMSO In stead of 10 ng/ml HGF 1.4 μM BIO WME + SQ 0.5% DMSO (− GA1000) + 10 mM 1% Glutamax + Nicotinamide 0.1% PEST). ITS (1x, 10 μl/ml) 3 ng/ml glucagon M5 M6 WME + SQ WME + SQ (−GA1000) (−GA1000) (+1% Glutamax + (+1% Glutamax + 0.1% PEST) 0.1% PEST) 2 ng/ ml bFGF 2 ng/ ml bFGF 20 ng/ ml HGF 20 ng/ ml HGF 10 ng/ml OsM 0.1 μM DexM -
FIG. 10 . - Induction of CYP Activities in 3D Scaffolds.
- Induction of CYP3A and CYP2C9 activity by measuring the metabolic product of Midazolam, 4-OH Midazolam after 24 hours induction with or without 1 mM Phenobarbital and 10 uM Dexamethasone (induced/non-induced). During the 24 hours induction, Dexamethasone, DMSO and Bio was left out from the medium composition M1. After induction, the activity assay was performed as described elsewhere (see Example 6).
-
FIG. 11 a. - Verification of Embryonic Endoderm Fate of hESC Cells Cultured on 2D Prior to Seeding on 3D Scaffolds.
- Induction of endoderm markers (FoxA2, HHex, CxcR4, CER1) and downregulation of pluripotency markers (Sox7, Nanog, Oct4) in hESC cells cultured in 2D format for 7 days prior to seeding on 3D scaffolds; two independent cell lines (SA121 and SA181) cultured according to protocol a) on matrigel-coated 2D surface. Brightfield morphology of cells is also shown.
-
FIG. 11 b. - Verification of Embryonic Endoderm Fate of iPS Cells Cultured on 2D Prior to Seeding on 3D Scaffolds.
- Induction of endoderm markers (FoxA2, HHex, CxcR4, CER1) in iPS cells cultured in 2D format for 7 days prior to seeding on 3D scaffolds; cell line IMR90 cultured according to protocol h (exp169a) and f (exp169b)
-
FIG. 12 . - Verification of Hepatic Progenitor Fate of hESC Cells Cultured on 2D Prior to Seeding on 3D Scaffolds.
- Induction of hepatic progenitor markers (AFP, EpCAM, FOXA2, HNF4-a, KRT19, KRT8) in hESC cells cultured in 2D format for 11 days prior to seeding on 3D scaffolds; cell lines SA121 and SA181, cultured according to protocol g).
-
- Baharvand, H. et al. (2006) Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro. (2006) 50: 645-652
- Berthiaume, F. et al. (1996) Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration. FASEB J. 10: 1471-1484
- Blumenthal, B. et al. (2010) Polyurethane scaffolds seeded with genetically engineered skeletal myoblasts: a promising tool to regenerate myocardial function. Artif. Organs 34: E46-54
- a. Bokhari, M. et al. (2007) Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. J. Anat. 211: 567-576
- b. Bokhari, M. et al. (2007) Novel cell culture device enabling three-dimensional cell growth and improved cell function. Biochem. Biophys. Res. Commun. 354: 1095-1100
- Dunn, J. C. et al. (1991) Long term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol. Prog. 7: 237-245
- Dvir-Ginzberg, M. et al. (2003) Liver tissue engineering within alginate scaffolds: effects of cell-seeding density on hepatocyte viability, morphology and function. Tissue Eng. 9: 757-766
- Dvir-Ginzberg, M. et al. (2008) Induced differentiation and maturation of newborn liver cells into functional hepatic tissue in macroporous alginate scaffolds. FASEB J. 22: 1440-1449
- Elkayam, T. et al. (2006) Enhancing the drug metabolism activities of C3A-a human hepatocyte cell line-by tissue engineering within alginate scaffolds. Tissue Eng. 12: 1357-1368
- Hamilton, G. A. et al. (2001) Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res. 306: 85-99
- Heins, N. et al. (2004) Derivation, characterization, and differentiation of human embryonic stem cells. Stem Cells 22: 367-376
- Matsumoto, K. et al. (2008) Hepatic differentiation of mouse embryonic stem cells in a three-dimensional culture system using polyurethane foam. J. Biosci. Bioeng. 105: 350-354
- Piryaei, A. et al. (2010) Differentiation of Bone Marrow-derived mesenchymal stem cells into hepatocyte-like cells on nanofibers and their transplantation into a carbon tetrachloride-induced liver fibrosis model. Stem Cell Rev. February 25 (Epub ahead of print)
- Rambhatla, L. et al. (2003) Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant 12: 1-11
- Shapiro, L & Cohen, S. (1997) Novel alginate sponges for cell culture and transplantation. Biomaterials 18: 583-90
- Takahashi, K. et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872
- Thomson, J. A. et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-1147
- Wang, S. et al. (2008) Three-dimensional primary hepatocyte culture in synthetic self-assembling peptide hydrogel. Tissue Eng. Part A 14: 227-236
- Yu, J. et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920
Claims (31)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/703,495 US9127255B2 (en) | 2010-06-11 | 2011-06-14 | 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35367810P | 2010-06-11 | 2010-06-11 | |
DK201000515 | 2010-06-11 | ||
DKPA201000515 | 2010-06-11 | ||
DKPA201000515 | 2010-06-11 | ||
PCT/EP2011/059773 WO2011154552A1 (en) | 2010-06-11 | 2011-06-14 | 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes |
US13/703,495 US9127255B2 (en) | 2010-06-11 | 2011-06-14 | 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes |
Publications (3)
Publication Number | Publication Date |
---|---|
US20130164266A1 US20130164266A1 (en) | 2013-06-27 |
US20130336933A9 true US20130336933A9 (en) | 2013-12-19 |
US9127255B2 US9127255B2 (en) | 2015-09-08 |
Family
ID=42309459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/703,495 Expired - Fee Related US9127255B2 (en) | 2010-06-11 | 2011-06-14 | 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes |
Country Status (7)
Country | Link |
---|---|
US (1) | US9127255B2 (en) |
EP (1) | EP2580319B1 (en) |
JP (2) | JP6025715B2 (en) |
CN (1) | CN103097517A (en) |
AU (1) | AU2011263652B2 (en) |
CA (1) | CA2805165A1 (en) |
WO (1) | WO2011154552A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130280804A1 (en) * | 2010-12-31 | 2013-10-24 | Stephen Dalton | Differentiation of human pluripotent stem cells to multipotent neural crest cells |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9157908B2 (en) | 2011-04-22 | 2015-10-13 | University Of Washington Through Its Center For Commercialization | Chitosan-alginate scaffold cell culture system and related methods |
JP6024047B2 (en) * | 2012-06-04 | 2016-11-09 | 国立大学法人京都大学 | Method for culturing pluripotent stem cells and substrate therefor |
USD1009775S1 (en) | 2014-10-15 | 2024-01-02 | Maxeon Solar Pte. Ltd. | Solar panel |
USD933584S1 (en) | 2012-11-08 | 2021-10-19 | Sunpower Corporation | Solar panel |
WO2015081226A1 (en) | 2013-11-27 | 2015-06-04 | The Johns Hopkins University | Engineered cardiac derived compositions and methods of use |
JP6791756B2 (en) * | 2014-01-21 | 2020-11-25 | ザ メディカル カレッジ オブ ウィスコンシン インクThe Medical College Of Wisconsin, Inc. | Methods for Selective Inhibition of Pluripotent Stem Cells |
GB201406716D0 (en) * | 2014-04-15 | 2014-05-28 | Insphero Ag | Method of preparing cells for 3D tissue culture |
CA2950559C (en) | 2014-05-30 | 2023-09-19 | Kuraray Co., Ltd. | Culture method and cell cluster |
USD999723S1 (en) | 2014-10-15 | 2023-09-26 | Sunpower Corporation | Solar panel |
USD933585S1 (en) | 2014-10-15 | 2021-10-19 | Sunpower Corporation | Solar panel |
USD913210S1 (en) | 2014-10-15 | 2021-03-16 | Sunpower Corporation | Solar panel |
USD896747S1 (en) | 2014-10-15 | 2020-09-22 | Sunpower Corporation | Solar panel |
EP3239293A4 (en) * | 2014-12-24 | 2018-08-08 | Kyoto University | Endodermal cell production method, liver cell production method, pancreatic cell production method, endodermal cell induction promoter, liver cell induction promoting kit, pancreatic cell induction promoting kit, and micro fluid device |
HUE041518T2 (en) * | 2015-02-20 | 2019-05-28 | Inst Nat Sante Rech Med | Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells |
US20180147242A1 (en) * | 2015-03-18 | 2018-05-31 | The University Of Tokyo | Hepatocytes and hepatic non-parenchymal cells, and methods for preparation thereof |
CN104782583B (en) * | 2015-04-29 | 2017-04-12 | 中国农业科学院兰州兽医研究所 | In-vitro three-dimensional cultivation model for hydatid cysts and application thereof |
KR20180068997A (en) | 2015-10-15 | 2018-06-22 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | METHOD AND APPARATUS FOR THE PRODUCTION OF INTERBITROS STRUCTURE |
EP3397753B1 (en) * | 2015-12-30 | 2021-10-27 | FUJIFILM Cellular Dynamics, Inc. | Microtissue formation using stem cell-derived human hepatocytes |
US20200377863A1 (en) * | 2016-02-10 | 2020-12-03 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
CN110312788A (en) * | 2016-06-21 | 2019-10-08 | 江苏大学 | A kind of cell reprogramming method based on three-dimensional system |
CN106075586B (en) * | 2016-07-19 | 2019-05-24 | 东华大学 | Cultural method based on adult stem cell-regenerated silk fibroin tissue engineering bracket artificial liver repair materials |
AU2017363878A1 (en) * | 2016-11-22 | 2019-06-13 | Nutech Ventures | Personalized cellular biomanufacturing with a closed, miniature cell culture system |
JP6711424B2 (en) | 2017-02-01 | 2020-06-17 | 株式会社島津製作所 | Cell culture gel composition and method for producing the same, cell culture method and cell culture substrate |
JP7285783B2 (en) * | 2017-03-10 | 2023-06-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Infected cell culture |
WO2018182356A1 (en) * | 2017-03-31 | 2018-10-04 | (주)안트로젠 | Culture containing high concentration of mesenchymal stem cell-derived high-purity exosome, and preparation method therefor |
US11407979B2 (en) | 2017-09-01 | 2022-08-09 | Colorado State University Research Foundation | Intermittent starvation techniques to prolong functional lifetime of liver cells in culture |
CN107904207A (en) * | 2017-11-13 | 2018-04-13 | 广东艾时代生物科技有限责任公司 | A kind of method for obtaining mature hepatocytes using three dimensional culture system induction people inductive pluripotent stem cells |
CN109337858B (en) * | 2018-09-20 | 2022-03-15 | 中国人民解放军第二军医大学 | Liver precursor sample cell model of primary hepatocyte source for hepatitis B virus infection, preparation method and application |
MA55314A (en) * | 2019-03-14 | 2022-01-19 | Sanford Burnham Prebys Medical Discovery Inst | BIODEGRADABLE SCAFFOLD FOR HAIR GROWTH AND METHODS OF USE |
WO2021065849A1 (en) * | 2019-09-30 | 2021-04-08 | 富士フイルム株式会社 | Medium for culturing hepatocytes, production method for hepatocytes, and hepatocytes |
WO2021200235A1 (en) * | 2020-03-31 | 2021-10-07 | 国立大学法人 東京大学 | Method for producing three-dimensional intestinal tissue model |
CN111467579B (en) * | 2020-04-03 | 2021-10-26 | 北京臻溪谷医学研究中心(有限合伙) | Alloy-core-based stem cell stent for treating aneurysm and vascular stenosis and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090123432A1 (en) * | 2007-07-20 | 2009-05-14 | Cellartis Ab | Novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts derived stem cells |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05308953A (en) * | 1992-05-13 | 1993-11-22 | Asahi Medical Co Ltd | Cell culture membrane |
US7282366B2 (en) | 2000-04-27 | 2007-10-16 | Geron Corporation | Hepatocytes for therapy and drug screening made from embryonic stem cells |
JP2007000038A (en) * | 2005-06-22 | 2007-01-11 | Toray Ind Inc | Closed-system circulatory circuit-type culturing device |
CN1844373A (en) * | 2006-04-28 | 2006-10-11 | 华东理工大学 | Method for in vitro preparation of hepatocyte induced by umbilical cord blood hematopoietic stem cell |
CA2650488A1 (en) | 2006-04-28 | 2007-11-08 | Reinnervate Limited | Substrate for the growth of cultured cells in three dimensions |
WO2008106771A1 (en) | 2007-03-02 | 2008-09-12 | Mark Ungrin | Devices and methods for production of cell aggregates |
US20080299601A1 (en) | 2007-03-15 | 2008-12-04 | Invitrogen Corporation | Adhering Surfaces |
JP5620631B2 (en) * | 2007-05-23 | 2014-11-05 | 三菱レイヨン株式会社 | Cell culture scaffold material, manufacturing method thereof, cell culture module |
EP2183289A2 (en) | 2007-08-31 | 2010-05-12 | Corning Incorporated | Reactive surface on a polymeric substrate |
GB0817990D0 (en) | 2008-10-02 | 2008-11-05 | Reinnervate Ltd | Cell culture vessel |
US20100297675A1 (en) | 2008-11-24 | 2010-11-25 | Huayun Deng | Substrate and method for culturing breast cells |
CN101428154B (en) * | 2008-12-04 | 2013-10-30 | 浙江大学 | Implantation type artificial hepar |
US9284531B2 (en) * | 2009-06-18 | 2016-03-15 | Takara Bio Europe Ab | Differentiation of human pluripotent stem cells into cells expressing mature hepatocyte markers by 2D and bioreactor culture |
-
2011
- 2011-06-14 AU AU2011263652A patent/AU2011263652B2/en not_active Ceased
- 2011-06-14 US US13/703,495 patent/US9127255B2/en not_active Expired - Fee Related
- 2011-06-14 WO PCT/EP2011/059773 patent/WO2011154552A1/en active Application Filing
- 2011-06-14 CA CA 2805165 patent/CA2805165A1/en not_active Abandoned
- 2011-06-14 CN CN2011800372371A patent/CN103097517A/en active Pending
- 2011-06-14 JP JP2013513715A patent/JP6025715B2/en not_active Expired - Fee Related
- 2011-06-14 EP EP11728211.1A patent/EP2580319B1/en not_active Not-in-force
-
2016
- 2016-07-04 JP JP2016132581A patent/JP2016171820A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090123432A1 (en) * | 2007-07-20 | 2009-05-14 | Cellartis Ab | Novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts derived stem cells |
Non-Patent Citations (6)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130280804A1 (en) * | 2010-12-31 | 2013-10-24 | Stephen Dalton | Differentiation of human pluripotent stem cells to multipotent neural crest cells |
US10053667B2 (en) | 2010-12-31 | 2018-08-21 | University Of Georgia Research Foundation, Inc. | Differentiation of human pluripotent stem cells to multipotent neural crest cells |
Also Published As
Publication number | Publication date |
---|---|
EP2580319B1 (en) | 2016-07-20 |
JP2016171820A (en) | 2016-09-29 |
EP2580319A1 (en) | 2013-04-17 |
AU2011263652A1 (en) | 2013-01-24 |
CN103097517A (en) | 2013-05-08 |
US20130164266A1 (en) | 2013-06-27 |
WO2011154552A1 (en) | 2011-12-15 |
JP6025715B2 (en) | 2016-11-16 |
AU2011263652B2 (en) | 2014-11-20 |
JP2013532966A (en) | 2013-08-22 |
CA2805165A1 (en) | 2011-12-15 |
US9127255B2 (en) | 2015-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9127255B2 (en) | 3-dimensional scaffolds for improved differentiation of pluripotent stem cells to hepatocytes | |
US10106777B2 (en) | Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of Wnt-signalling pathway | |
Talkhabi et al. | Human cardiomyocyte generation from pluripotent stem cells: A state-of-art | |
CN102083967B (en) | A novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts stem cells | |
US8278105B2 (en) | Induction, propagation and isolation of liver progenitor cells | |
Van Hoof et al. | Differentiation of human embryonic stem cells into pancreatic endoderm in patterned size-controlled clusters | |
EP3397753B1 (en) | Microtissue formation using stem cell-derived human hepatocytes | |
Tasnim et al. | Functionally enhanced human stem cell derived hepatocytes in galactosylated cellulosic sponges for hepatotoxicity testing | |
CN105143445A (en) | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | |
SG184204A1 (en) | Culture method for causing differentiation of pluripotent mammalian cells | |
Dzobo et al. | Wnt/β-catenin and MEK-ERK signaling are required for fibroblast-derived extracellular matrix-mediated endoderm differentiation of embryonic stem cells | |
JP6421335B2 (en) | Method for culturing hepatic progenitor-like cells and culture thereof | |
Jones et al. | Cultivating liver cells on printed arrays of hepatocyte growth factor | |
EP3702444A1 (en) | Method for inducing differentiation of pluripotent stem cells into hepatocytes | |
Stephenson et al. | Induced pluripotent stem cell-derived vascular smooth muscle cells | |
JP2008148685A (en) | Carrier for culturing undifferentiated cell, and subculture method | |
Class et al. | Patent application title: 3-DIMENSIONAL SCAFFOLDS FOR IMPROVED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEPATOCYTES Inventors: Janne Jensen (Gothenburg, SE) Assignees: Cellartis AB | |
Pettinato et al. | Human embryoid bodies to hepatocyte-like clusters: Preparing for translation | |
WO2023162950A1 (en) | Liver organoid-derived cultured hepatocytes | |
Ren et al. | Feeder cells treated with ethanol can be used to maintain self‐renewal and pluripotency of human pluripotent stem cells | |
Pettinato et al. | Liver Research | |
Haque et al. | Differentiation of Embryonic Stem Cells into Endoderm-Derived Hepatocytes | |
JP2019511219A (en) | Method of differentiating pluripotent stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELLARTIS AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JENSEN, JANNE;REEL/FRAME:029761/0890 Effective date: 20130110 |
|
ZAAA | Notice of allowance and fees due |
Free format text: ORIGINAL CODE: NOA |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
AS | Assignment |
Owner name: TAKARA BIO EUROPE AB, SWEDEN Free format text: CHANGE OF NAME;ASSIGNOR:CELLARTIS AB;REEL/FRAME:035903/0917 Effective date: 20140918 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20230908 |